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Abstract 
Precise control over transcriptional regulation is required for normal cell function.  Errors 
in transcriptional regulation underpin many diseases including cancer.  Thymine DNA 
Glycosylase (TDG) is a base excision repair protein and a coregulator that has been 
implicated in a diverse set of fundamental biological processes including embryonic 
development, nuclear receptor signaling and Wnt signaling.  Importantly, TDG has been 
shown to play an important role in transcriptional regulation in a wide variety of systems.  
Details surrounding the mechanism through which TDG acts remain unclear.  In this thesis 
I explore the role of TDG in Estrogen Receptor (ER)-dependent signaling and in cellular 
senescence. 
To characterize the role of TDG in ERα mediated signaling I first mapped β-Estradiol (E2)-
dependent DNA binding of TDG in the MCF7 breast cancer cell line using ChIP-Seq.  
Using bioinformatics in conjunction with more traditional biochemistry techniques I 
established that a significant component of TDG binding occurs at enhancers, where it was 
able to mediate the production of enhancer RNA (eRNA) and 3-dimensional reorganization 
of transcriptional units.  Knockdown of TDG disrupts E2-mediated upregulation of ER-
targets and inhibits growth.  Remarkably, in addition to behavior mimicking that of an 
oncogene, I find that TDG knockdown and depletion result in a much more aggressive 
phenotype, revealing its role as a potential potent tumor suppressor. 
To explore the role of TDG in cellular senescence I induced senescence in IMR90 human 
fibroblasts using hydrogen peroxide (H2O2) and monitored markers of senescence, 
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including proliferation and β-galactosidase staining.  I found that while senescence was 
readily inducible in this cell line using H2O2, knockdown of TDG was able to significantly 
impede the process. Using ChIP, I found that TDG was recruited to a CpG island 
overlapping the CDKN2A promoter, a tumor suppressor important for senescence.  Further 
studies including ChIP, bisulfite sequencing and conventional assays revealed that TDG is 
required for H2O2-mediated transcription of CDKN2A in a CBP-dependent and active-
demethylation independent manner.  
Collectively, these studies extend the role of TDG in transcriptional regulation, implicating 
it as a mediator of cellular senescence and as a mediator of eRNA transcription and 3-
dimensional re-organization in hormone signaling. 
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1.1 Overview  
Multicellular organisms are composed of a variety of cell types that perform specialized 
functions critical to an organism’s survival. Diverse cell types within the same organism 
often contain the same set of DNA yet can exhibit very different morphologies and 
functions. This discrepancy is resolved by the observation that a cell’s phenotype is 
controlled not by the set of genes it possesses, but rather by which genes are expressed: 
transcribed into RNA and ultimately translated into protein.  As such, cells of the same 
“type” often share expression profiles that closely resemble one another but differ from 
cells of a different type. Changes to a normal cell’s expression profile can result in changes 
to its established function and morphology. When this occurs more generally, an 
organism’s fitness can become impacted.  For example, during embryonic development, 
where cells progress from undifferentiated stem cells to differentiated cells with specific 
functions, control of transcription is particularly critical and disruption to the 
transcriptional program can result in developmental errors that can be lethal (Cortázar et 
al., 2011; Cortellino et al., 2011; Li et al., 1992). Loss of transcriptional regulation and 
subsequent disruption of expression patterns is also observed to underlie numerous 
pathologies.  A consistent feature found in many cancers is that the transcription of tumor 
suppressors and oncogenes are often dysregulated (Bihl et al., 2012; Frietze et al., 2014; 
Zheng and Blobel, 2010).  Therapeutically, targeting defects in expression in order to re-
establish ‘normal’ expression patterns has been used successfully to treat some diseases:  
in the case of cancer these act primarily by silencing oncogenes or re-establishing 
expression of some tumor suppressors (Morris and Chan, 2015). Building a deeper 
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understanding of transcriptional regulation may provide insight into pathologies with an 
underlying dysregulation of transcription.   
An important component of transcriptional regulation are the coregulators which can 
further be subdivided into “coactivators” and “corepressors”. Coregulators are proteins that 
modulate transcription of DNA by controlling the transcriptional machinery’s accessibility 
to the DNA. This is achieved either directly, by altering the chromatin structure through 
covalent modification to the DNA and/or associated histones, or indirectly, acting as 
scaffolds which then recruit other proteins that can then modify the chromatin. Thymine 
DNA Glycosylase (TDG) is a coregulator that has been implicated in a diverse set of 
fundamental biological processes including embryonic development, nuclear receptor 
signaling and Wnt signaling.  While TDG has been shown to regulate transcription in a 
wide variety of systems, details surrounding its mechanism of action remain unresolved.  
In this thesis I seek to extend our knowledge of transcriptional regulation by exploring the 
role of TDG in different contexts. Specifically, I investigate TDG’s role in estrogen 
receptor dependent signaling and in cellular senescence. 
 
1.2 Eukaryotic Transcriptional Regulation 
The establishment and maintenance of correct expression profiles is required by all 
biological process from development to fully differentiated tissues. Deviations from 
normal expression patterns are often observed in cells during disease development and can 
be directly responsible for the pathological changes to a cell’s phenotype.  Transcription of 
DNA to its corresponding RNA and finally translation to the protein product is a highly 
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regulated process with multiple checkpoints along the way.  Because it requires a 
considerable investment of energy and resources, regulation during the initial stages is 
much more efficient as it prevents the cell from unnecessarily wasting resources and 
energy. One of the earliest points of regulation occurs during the transcription of DNA to 
RNA.  Control at the transcriptional level can be broadly categorized into 2 distinct, but 
intimately related mechanisms: Transcription factor dynamics at regulator regions as well 
as epigenetic control over accessibility to these regions.  
 
1.2.1 Transcriptional Regulatory Regions 
Transcription occurs through 3 distinct stages: 
(1) Initiation - the localization and assembly of critical transcriptional machinery, RNA Pol 
II and its auxiliary factors to the targeted gene’s regulatory regions.  
(2) Elongation -  The process whereby RNA Pol II transverses the DNA template and 
assembles the RNA molecule.  
(3) Termination – Dissociation of RNA Pol II from DNA template. 
The initiation stage of transcription is a particularly important point of regulation as the 
cell has not yet invested energy or resources at this point. During this stage, the 
transcriptional machinery is typically localized to the gene’s regulatory regions, which 
contain elements critical for its transcription. Transcriptional initiation requires the 
formation of a “pre-initiation complex” (PIC) that consists of, at a minimum, RNA Pol II 
(the enzyme responsible for synthesizing the RNA molecule from DNA template) and its 
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6 general auxiliary factors (TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH) (Luse, 2013). 
The promoter, a region of DNA adjacent to the gene and often encompassing the 
transcriptional start site, contains regions that facilitate the formation of this complex.  The 
promoter often contains a B recognition element (BRE), a downstream promoter element 
(DPE) and the “initiator element” or a TATA box.  Generally, the presence of the TATA 
box and initiator element is mutually exclusive: promoters tend to have one, but not both, 
of these elements. During transcriptional initiation, these highly conserved elements are 
recognized and bound by auxiliary factors (either TFIID or TFIIB) which then results in 
further sequential binding of the additional auxiliary factors and RNA Pol II itself, forming 
the PIC. While the PIC is sufficient to produce minimal levels of transcription, in order to 
achieve the levels that often observed in vivo, an additional class of molecules called 
‘transcription factors’ must be recruited.   
 
1.2.2 Transcription Factors 
Transcription factors are proteins that regulate transcription at the point of transcriptional 
initiation, by facilitating or inhibiting loading of the PIC (Petrykowska et al., 2008).  
Conservative estimates put the number of transcription factors at approximately 1,300 
(approximately 6% of the protein coding genes in the human genome) (Vaquerizas et al., 
2009).  Transcription factors can be broadly classified into two mechanistic categories: (1) 
General transcription factors which include RNA Polymerase II and its auxiliary factors 
that form the pre-initiation complex and which are ubiquitously expressed in tissues and 
(2) Sequence specific transcription factors which recognize and bind to specific sequences 
of DNA and which are frequently expressed in a tissue-specific fashion.   
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Structurally, specific transcription factors are often composed of multiple domains that 
each serve distinct functions: 
(1) DNA binding domain - a structural motif often composed of alpha helices, beta 
sheets, and/or disordered regions that recognizes and binds specific DNA sequences 
termed ‘response elements’ or ‘transcription factor binding motifs’. A DNA binding 
motif can take many forms, for example the most common motifs include the helix-
loop-helix domain that is characterized by a simple structure of two α-helices linked by 
a loop, the  “zinc finger” domain, whose activity and structure requires the presence of 
one or more zinc ions, as well as structurally more complex domains such as the 
“winged-helix transcription factors” which are composed of four helices and a two-
strand beta-sheet (Yusuf et al., 2012).  
(2) Signal sensing domain – This domain allows transcription factors to respond to the 
presence of endogenous or exogenous molecules by altering their activity and/or 
localization.  A well-studied example of this is the Estrogen Receptor α (ER), a nuclear 
hormone receptor that underlies sexual and reproductive development in females.  ERα 
is found mostly in the cytoplasm under normal conditions (Putnik et al., 2012).  Upon 
binding β-Estradiol (E2), an ERα agonist, ERα molecules undergoes a conformational 
change, dimerizing and translocating into the nucleus where they bind to “Estrogen 
Response Elements”, a specific DNA sequence recognized by ERα and found in the 
regulatory region of ER-target genes. Recruitment of additional factors follows ERα 
binding, resulting in transcriptional upregulation of the ERα target genes (Carroll et al., 
2006; Hah et al., 2013; Welboren et al., 2009). 
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(3) Transactivation domain – In order to significantly impact transcription levels of a 
target gene, the recruitment of an additional class of proteins called “coregulators” is 
often required.  The transactivation domain is a series of amino acids that function as a 
scaffold capable of recruiting certain coregulators. Both transcription factors and 
coregulators can have multiple interaction domains that allow for each to interact with 
multiple partners.  For example, p53 contains two transactivation domains that are a 
part of the “Nine Amino Acid Transactivation Domain” a family of transactivation 
domains common to many eukaryotic transcription factors. This transactivation domain 
interacts with specific protein binding domains including the “TAZ1” and “KIX” 
domains which are both found on coregulators such as, CBP/p300.  The interaction 
between these domains and those of p53 is required for CBP/p300 recruitment and 
activity at sites of p53 binding (Kasper et al., 2011; Lee et al., 2010).  
Transcription factors can be regulated through transcriptional silencing and through post-
translational modifications that can either enable or prevent them from binding to their 
respective response elements. This is important, as the transcription levels of a specific 
gene are often dictated not by a single transcription factor, but rather by the collective 
effects of the transcription factors bound to its regulatory region.  Certain transcription 
factors are only present in particular cell types, allowing those cells to respond to a 
particular stimulus in a manner entirely distinct from cell types that expresses a different 
set of transcription factors.  This “combinatorial system” of transcriptional regulation 
allows an organism to respond to a vast and diverse set of exogenous and endogenous cues, 
while limiting the required genome size and the amount of transcription factors needed 
(Reményi et al., 2004; Vaquerizas et al., 2009). 
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1.2.3 Coregulator-mediated regulation of chromatin 
In eukaryotic cells, DNA is stored in a complex with protein and RNA called ‘chromatin’ 
(Figure 1-1).  The fundamental subunit of chromatin is the nucleosome consisting of 
approximately 147 base pairs (bp) of DNA wrapped around an octamer of positively 
charged histone proteins containing two of each of H3, H4, H2A and H2B (Eickbush and 
Moudrianakis, 1978). Nucleosomes are separated by short stretches of ‘linker’ DNA 
approximately 80 bp in length. Chromatin at this level of organization is referred to as 
‘euchromatin’ and when viewed under an electron microscope resemble ‘beads on a string’ 
(Figure 1-2) (Cann and Dellaire, 2011). The next level of organization involves “linker” 
histone H1, a non-core histone protein that binds outside of the core nucleosome at the 
location where the DNA enters/exits the nucleosome and that also interacts with the region 
of linker DNA that connect histones.  Histone H1 interactions stabilize the DNA into a 
further compacted, “30nm fiber” (debate however still exists as to the specific structure 
this fiber takes) (Cann and Dellaire, 2011). Chromatin at this level of organization is often 
referred to as heterochromatin. Chromatin generally exists in a heterogenous state 
composed of both euchromatin and heterochromatin, however during specific stages of the 
cell cycle (i.e. mitosis/meiosis), chromatin is further compacted into chromosomes in 
preparation for cellular division.  
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Figure 1-1.  Progressive levels of chromatin compaction. 
Incorporation of linker histone H1 generally marks the transition from a euchromatin 
(favorable to transcription) to heterochromatin (transcriptionally repressed state). 
(With modification from source: 
https://commons.wikimedia.org/wiki/File:Chromatin_Structures.png) 
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Figure 1-2. Electron micrograph of ‘11nm chromatin fiber’.  
Also referred to as “beads on a string” the chromatin in this state is composed of 
nucleosome units (black brackets), that can be further resolved to nucleosomes (black 
arrowhead) and DNA linker region (white arrowhead). (Original image by Chris 
Woodcock, doi:10.7295/W9CIL709) 
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Chromatin structure is inherently linked to transcriptional activity: the ‘relaxed’ 
organization of euchromatin readily allows the transcriptional machinery to gain access to 
DNA and is therefore often found in regions that are transcriptionally active.  
Heterochromatin, which is a highly compacted structure, masks the underlying DNA from 
the transcriptional machinery, inhibiting access to general and most sequence specific 
transcription factors, and is therefore often found associated with transcriptionally silent 
areas of the genome. An exception to this is a class of transcription factors called ‘pioneer 
factors’ which possess a certain structure that allows them to bind heterochromatinized 
DNA.  Once bound to DNA, transcription factors often recruit another class of proteins, 
called ‘coregulators’, that dynamically alter the chromatin landscape, either making it more 
or less permissible to transcription.  Therefore, whether a transcription factor has a positive 
or negative effect on transcriptional activity is often dictated by the coregulators it recruits. 
Coregulators can alter the structure of chromatin primarily through two methods: (1) The 
removal of nucleosomes through an ATP-dependent process, and/or (2) post-translational 
modifications of histones. Post-translational modifications often occur in the form of 
covalent addition of an acetyl, methyl or phosphoryl group to specific residues on 
unorganized regions of the histone that protrude out from the nucleosome referred to as 
histone ‘tails’ (Figure 1-3) (Eickbush and Moudrianakis, 1978). The addition or removal 
of these modifications can alter the affinity between the DNA and histones which leads to 
either a relaxing or tightening of the chromatin structure that, in turn, impacts transcription 
levels.  In the case of histone acetylation for example, addition of acetyl groups to specific 
lysine residues on the histone tails neutralizes the positive charge on the histones disrupting 
their affinity for negatively charged DNA. 
14 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3. Histone tail modifications. 
Schematic highlighting potential histone tail modifications that have been observed.  
Generally, only a subset of these will be present on any one nucleosome.  At any one 
particular site acetylation and methylation can be found to be mutually exclusive, targeting 
the same residue. 
(Source: Wikimedia Commons. Author: Mariuswalter; Based on work from Rodriguez-
Paredes and Esteller, Nature, 2011) 
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 This weakened affinity promotes an ‘open’ chromatin state, encouraging transcriptional 
machinery access.  Coregulators that catalyze this reaction, called histone 
acetyltransferases, are therefore often referred to more specifically as “coactivators” as 
their presence strongly corresponds to increased transcriptional activity.  In contrast, 
coregulators that contain histone deacetylase activity, remove acetyl groups from histones, 
and therefore exert the opposite effect: they reestablish the positive charge on histones 
which increases the affinity for DNA promoting a more organized chromatin structure that 
is less accessible to the transcriptional machinery.  Coregulators with histone deacetylase 
activity are therefore often referred to as “corepressors” and are often found at 
transcriptionally silenced genomic regions.   
The relationship between histone methylation and transcription is more complex because 
methylation of specific residues can correspond to either transcriptional silencing or 
activation depending on the location and the abundance of methyl marks that are deposited.  
For example, trimethylation of lysine 27 on Histone H3 (H3K27me3), which is catalyzed 
by EZH2, a component of the polycomb repressive complex 2, is found exclusively at 
transcriptionally silenced regions, while monomethylation of the same site (i.e. 
H3K27me1) is strongly associated with active transcription (Barski et al., 2007).  
Importantly, genomic regions contain numerous nucleosomes that are each composed of 
multiple histones, and each histone has multiple sites that can be modified. While certain 
histone modifications are strongly correlated with the expression or repression of any given 
region, it is the specific permutation of histone modifications (i.e. the “Histone code”) that 
best correlates with the coactivator composition at that region and its transcriptional status. 
In addition to altering the affinity between the DNA and histones, addition or removal of a 
17 
 
 
 
specific modification from a histone residue can also create binding sites for factors that 
can recognize a particular modification or, conversely, mask such a site – further 
complicating the effects that covalent modifications may have in any given context.   
 
1.2.4 DNA Methylation and Active Demethylation 
In addition to changes in the organization of chromatin, modifications to the DNA 
molecule, primarily in the form of covalent modifications to cytosine, can have profound 
effects on transcriptional regulation (Aran and Hellman, 2013).  Cytosine can be covalently 
modified primarily in a CpG context. DNA methylation patterns are maintained by DNA 
methyltransferases (DNMTs) which recognize unmethylated/hemi-methylated DNA and 
catalyze the transfer of a methyl group from S-adenosylmethionine (SAM) to the C5 carbon 
of cytosine, creating 5-methylcytosine (5mC). Remarkably, while most CpG’s in normal 
tissue are methylated, promoters often contain long stretches of CpGs (CpG islands) which 
are maintained in an un-methylated state (Feltus et al., 2003). Hyper-methylation of these 
promoters is strongly associated with transcriptional repression of the associated gene(s) 
(Baylin and Herman, 2000).  Mechanistically, 5mC can repress transcription either directly 
by making regulatory sites inaccessible to transcription factor binding, or indirectly 
through the recruitment of proteins that contain methyl-binding domains which in turn, 
recruit additional proteins which have repressor activity.   
Patterns of global methylation and promoter-specific hypomethylation are maintained in 
healthy tissue (Baylin and Herman, 2000). However, in most cancers DNA methylation is 
highly dysregulated consisting of global hypomethylation and promoter-specific 
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hypermethylation.  Global hypomethylation has been proposed to have an oncogenic effect 
by activating epigenetically silenced transposable elements or endogenous viruses, as well 
as increased rates of chromosomal rearrangements (Chen et al., 1998b). Furthermore, many 
tumor-suppressor genes contain CpG islands in their promoters that are hypermethylated 
in cancer and are transcriptionally silenced. Importantly, DNA methylation inhibitors can 
reactivate epigenetically silenced tumor suppressors and have been used therapeutically 
(Licht, 2015).  While the mechanism governing DNA methylation has been extensively 
researched and is well characterized, the mechanism(s) governing DNA demethylation 
have proven to be more elusive.  
DNA demethylation can occur through both active and passive pathways.  The passive 
pathway is achieved primarily through the loss of DNMT activity.  In oocytes this is 
achieved primarily through the exclusion of DNMT1 from the nucleus, while in primordial 
germ cells this is achieved through the down-regulation of UHRF1, a protein that targets 
DNMT1 to hemi-methylated DNA (Messerschmidt et al., 2014; Ratnam et al., 2002). 
During proliferation, this inability to methylate DNA results in the gradual dilution of the 
methylation signal over successive rounds of DNA replication. On average, cells would 
theoretically retain 50% of the number of methylated CpG’s that the previous generation 
had, meaning that after 9 cell divisions the retained percentage of methylation remaining 
would be approximately 0.2% of the first generation’s methylation levels. 
The first clues that an “active” demethylation process must exist came from the observation 
that  paternal DNA is almost entirely (80-90%) methylated prior to zygote formation, yet 
it becomes entirely de-methylated shortly thereafter, prior to DNA replication 
(Messerschmidt et al., 2014). Subsequent work has found that active demethylation is 
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wide-spread occurring in brain as well as skeletal muscle and has been reported to occur in 
response to extracellular signals such as TGFβ, retinoic acid, and fibroblast growth factor 
1 (FGF1) (Bruniquel and Schwartz, 2003; Guo et al., 2011; Zhang et al., 2007). 
While it was originally hypothesized that active demethylation occurs through direct 
enzymatic removal of the methyl group from cytosine (as is observed in certain plant 
species), no enzyme capable of this excision have been identified in human cells.  Instead, 
in mammalian systems, the removal of 5mC is dependent on a step-wise oxidation process, 
catalyzed by members of Ten Eleven Translocation (TET) family of proteins.  This 
iterative oxidation process starts at 5mC and first generates 5-Hydroxymethylcytosine 
(5hmC) which is then further oxidized by TET proteins to 5-Formylcytosine(5fC) and 
finally to 5-Carboxylcytosine(5caC) (Ito et al., 2011).  5fC and 5caC are then cleaved by 
TDG which, in a highly coordinate series of steps involving APE1 and members of the 
Base Excision Repair pathway, re-establishes an unmodified cytosine at the site (Maiti and 
Drohat, 2011) (figure 1-4).  
Active demethylation has been primarily investigated in the context of promoters, where 
TDG-dependent demethylation was required for expression of gene-target(s). However, 
recent work in embryonic stem cells has found that TDG depletion results in the 
accumulation of 5mC metabolites at distal enhancers (Song et al., 2013; Wheldon et al., 
2014). While methylation status of promoters strongly correlates with gene expression, an 
analysis of 390 ER-positive breast tumors revealed that methylation of distal sites corelates  
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Figure 1-4.  Active demethylation pathway.   
Recent studies have established that TET-mediated, iterative oxidation, followed by TDG 
excision and BER is likely the most prevalent method through which active demethylation 
is achieved in mammals. 
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to target gene expression more closely than promoter methylation.  The significance of this 
remains to be elucidated and the exact role that TDG-mediated active demethylation plays 
at enhancers in this context, remains unresolved.   
 
1.2.5 Enhancers and enhancer RNA (eRNA) 
In addition to proximal regulatory elements, regulatory regions can also be found large 
distances away (up to millions of bases away or on different chromosome altogether) from 
specific genes.  These regulatory regions, called ‘enhancers’, are able to mediate 
transcriptional activity of associated gene(s) (Jeong et al., 2014; Li et al., 2013; Ong and 
Corces, 2012; Yip et al., 2012).  
Functionally, enhancers share some similarities with promoters and often contain binding 
sites for transcription factors, RNA Pol II and components of the pre-initiation complex as 
well as coregulators (Plank and Dean, 2014).  Enhancers are often located in non-coding 
regions of DNA and, in response to an activating signal, some enhancers are transcribed to 
produce long non-coding RNA, termed ‘enhancer RNA’ (eRNA) (Lam et al., 2014; Li et 
al., 2013; Pulakanti et al., 2013).  While the role of eRNA still remains somewhat 
controversial, recent studies have confirmed that eRNA production, per se, causes 
conformational changes that bring the enhancer in direct contact with the target-gene 
promoter (Li et al., 2013).  This brings together transcription-factors, coregulators and 
RNA-Pol II bound at the enhancer and the basal transcriptional machinery positioned at 
the proximal promoter (figure 1-5). Disruption of either eRNA production or looping can 
prevent transcription of the associated gene (Li et al., 2013). 
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While conventional reporter/luciferase assays are still used to identify potential enhancers, 
recent developments in high-throughput sequencing have allowed us to gain unprecedented 
insight into their structure and function.  Poised or active enhancers are often found in 
‘open’ chromatin regions depleted of nucleosomes - allowing for transcription 
factor/coregulator accessibility (Pulakanti et al., 2013).  DNase-Seq and FAIRE-Seq are 
both techniques which can identify nucleosome depleted regions by digesting accessible 
DNA using DNase I or by depleting the histone-associated ‘closed’ regions, respectively.  
Unfortunately, these techniques alone provide an incomplete picture, as not all open 
regions are necessarily enhancers, and not all enhancers will necessarily be found in an 
‘open’ chromatin state.   
As identified by conventional biochemical techniques, enhancers are often sites of 
transcription factor and coactivator binding (Frietze et al., 2012).  This property has been 
used to predict/identify potential enhancers by searching for genomic regions outside of 
annotated gene’s that contain a cluster of transcription binding motifs or that contain a 
sequence conserved between species. However, the location of clustered transcription 
factor binding motifs or highly conserved sequence, does not necessarily mean that the 
region is an enhancer, as many transcription factor binding motifs are not actually bound 
by the transcription factor in vivo or are only bound by those TF’s in certain cells, or in 
certain contexts.  A more accurate way to identify/predict enhancer regions is through the 
identification of certain coregulator binding sites (Shlyueva et al., 2014).   
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Figure 1-5.  Schematic of Enhancer and Promoter in 'active' configuration.   
An example of a potential enhancer/promoter complex formed prior to release of Pol II and 
transcription.  The composition of components at enhancers differs depending on context, 
however certain elements (Activators, coactivators, RNA Pol II, etc.) appear to be required. 
  
25 
 
 
 
 
 
 
 
 
 
  
26 
 
 
 
Because coregulators do not bind DNA directly (rather they are largely recruited by their 
interaction with specific transcription factors), global ChIP-Seq targeting cofactors such as 
the lysine acetyltransferase CBP (or its homologue p300) would identify regions that are 
bound by both CBP/p300 and their interacting transcription factor, removing the noise from 
the cruder motif analysis or sequence conservation studies.  The binding of specific 
coactivators or corepressors to enhancers often results in histone markings that indicate the 
‘state’ of the enhancer.  For example, acetylation of histone H3 on Lysine 27 (H3K27Ac) 
is often found at enhancers and promoters that are actively being transcribed while 
H3K4me1, on the other hand, is a mark that is often found at enhancers but not at promoters 
(Bulger and Groudine, 2011; Lupien et al., 2008).  Regions that contain both H3K27Ac 
and H3K4me1, have been strongly associated with actively transcribed enhancers 
(Creyghton et al., 2010; Zentner et al., 2011).  Additionally, histone marks indicating 
repressed states also exist.  For example, H3K27me3 (Histone H3, Lysine residue 27, tri-
methylation) is often associated with transcriptional silencing and corresponds to the 
presence of the Polycomb complex, a protein complex that mediates silencing of target 
regions (Zentner et al., 2011). Collectively, the specific set of histone marks at an enhancer 
are often able to accurately characterize its state (i.e. “poised”, “silenced” and “active”) 
and are now widely used throughout enhancer related studies (Shlyueva et al., 2014). 
Because enhancers are often transcribed into eRNA, which have been shown to play 
functional roles in 3-dimensional re-organization, techniques that are able to directly assay 
for these features are extremely powerful ways to identify or predict enhancers.  Global 
Run-On Sequencing (GRO-Seq) is an accurate way to identify regions of the genome 
where RNA Pol II is actively engaged in transcription and has been used to identify 
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enhancers which produce eRNA in response to stimuli (Li et al., 2013).  Various techniques 
exist which can be used to identify chromosomal conformation such as Chromatin 
Interaction Analysis by Paired-End Tag Sequencing (ChIA-PET).  ChIA-PET allows for 
the capture of 3-dimensional interactions that occur at sites of a protein of interest.  As 
enhancers are often characterized by interaction with the promoter and transcription (of 
both eRNA from the enhancer and mRNA from the gene-target), ChIA-PET performed 
with RNA Pol II has been used to successfully identify regions which are bonafide 
enhancers partaking in promoter interactions (Fullwood et al., 2009; Li et al., 2012).  
Alone, or in combination, these techniques have allowed for the accurate identification and 
mapping of enhancers globally. 
Enhancers play a fundamental role in cell-specific transcriptional regulation and the 
importance of enhancers in human biology is wide-spread.  During embryonic 
development for example, where precise patterns of gene expression are required, 
enhancers play a fundamental role in controlling the spatial and temporal transcription of 
key modulators of embryonic development (Creyghton et al., 2010; Ong and Corces, 2012; 
Zhu et al., 2012). Errors in enhancer sequence can lead to a predisposition to many common 
diseases, including cancer. Global methylation studies examining the association between 
methylation and gene dysregulation in cancer in fact found that the transcript level of genes 
more strongly correlated to its enhancer methylation status than to the methylation status 
of its promoter (Aran and Hellman, 2013; Wiench et al., 2011).  A deeper understanding 
of enhancer regulation may be useful for treatment of pathologies that are underpinned by 
a dysfunctional regulation program. 
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1.3 Thymine DNA Glycosylase (TDG) 
TDG was originally discovered by protein purification of factors capable of binding and 
processing T:G mismatches in HeLa cells (Neddermann and Jiricny, 1993). TDG is, a 
member of the “Mismatch Uracil Glycosylase” (MUG) branch of the “Monofunctional 
Uracil-DNA Glycosylase” (UDG) superfamily. Members of this family are characterized 
by their ability to excise mismatched Uracils (G/T or G/U mispairs) from double-stranded 
DNA.  Structurally, TDG is composed of a catalytic ‘core’ flanked by N- and C- terminals. 
All three of its domains contain binding sites that mediate its physical interaction with a 
diverse set of proteins including components of the Base Excision Repair (BER), Nuclear 
Receptors (NRs), as well as additional coregulators (Figure 1-6).  Additionally, both the 
N- and C- terminals are targets of post-translational modifications that have been shown to 
alter the localization and activity of TDG (Hardeland et al., 2000; Hashimoto et al., 2013). 
 
1.3.1 TDG - Glycosylase Activity and Function 
While originally recognized as an enzyme capable of cleaving Thymine from T:G 
mismatches, subsequent work has revealed that TDG is capable of accommodating and 
processing a much broader set of substrates found at the cytosine position in a 
cytosine:guanine (CpG) context (Cortázar et al., 2007).   
The crystal structure has revealed that TDG’s catalytic domain forms a large hydrophobic 
pocket capable of accommodating various adducts and derivatives of uracil and cytosine 
including products resulting from oxidation, halogenation and deamination of these bases 
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and importantly, in the case of active demethylation, allows for the accommodation of the 
5mC derivatives 5fC and 5caC(Maiti and Drohat, 2011; Raiber et al., 2012; Shen et al., 
2013).  
The finding that TDG interacts with many transcription factors and coregulators suggests 
that it can be targeted to specific sites through interaction with its binding partners 
(Cortázar et al., 2007). Once localized to a site targeted for demethylation, TDG forms 
specific interactions with the base being targeted for removal, a guanine adjacent to the 
target site and importantly, the guanine opposite the base target for removal (Hashimoto et 
al., 2013). The interactions between TDG and both guanines is of particular importance as 
it allows for a control of specificity: interaction with the adjacent guanine confirms that 
TDG is at a CpG site and interaction with guanine from the opposite strand confirms that 
TDG is bound to double stranded DNA (Cortázar et al., 2007). These and other interactions 
stabilize TDG at the targeted site and result in TDG intercalating with the DNA in place of 
the targeted base, which is instead ‘flipped’ out of the double-helix and into the catalytic 
site of TDG, ultimately leading to its cleavage (Hashimoto et al., 2013).  Evidence for a 2nd 
TDG molecule being present and taking part in the interactions has also been shown 
(Cortázar et al., 2007).  Cleavage of the mispaired base by TDG creates an abasic site which 
is ‘nicked’ by Apurinic/apyrimidinic endonuclease (APE1). This process is highly 
coordinated – once TDG cleaves the mispaired base, it notably binds the abasic site with a 
high affinity.   
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Figure 1-6. Schematic of TDG Protein.   
Proteins known to interact with TDG are shown at approximate location where the 
interaction is believed to take place.  Regions known to be post translationally modified in 
certain contexts are marked: Ac - Acetylation, S – Sumoylation. 
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 In order to ensure that the components required to carry out the next series of steps are 
present, TDG dissociation from the abasic site requires both APE1 binding and 
SUMOylation of TDG (Waters et al., 1999). The site is then repaired by DNA Polymerase 
β and DNA ligase restoring an unmodified Cytosine at the site of repair.  
 
1.3.2 TDG as a Coactivator 
Evidence that TDG possesses functions independent of its glycosylase activity was first 
demonstrated in studies investigating the role of TDG in CBP/p300-dependent 
transcription (Tini et al., 2002).  Using a combination of immunoprecipitation, reporter and 
Avidin-biotin-coupled DNA assays, researchers demonstrated that TDG recruits and forms 
a complex with CBP/p300, stimulating its transcriptional activity (Tini et al., 2002). 
Importantly, inactivation of TDG’s glycosylase activity using a point mutation did not 
affect its ability to bind or stimulate CBP/p300-dependent transcription, suggesting that 
TDG may be behaving primarily as a coactivator. 
Further evidence for the coactivator role for TDG has emerged from work in Estrogen 
receptor signaling.  ERα, a member of the nuclear receptor family that is responsible for 
estrogen responsiveness in mammals and activation of ERα signaling has been implicated 
in breast cancer progression. It has been shown that TDG forms a complex with the ERα 
in response to ligand and localizes to ER-target promoters. Reporter assays directly testing 
the role of TDG in E2-mediated signaling revealed that TDG is a critical mediator of ER-
signaling and deletion of TDG inhibits transcription of ER-target genes.  Importantly, a 
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catalytically inactive mutant had no effect on TDG’s ability to mediate E2-transcription, 
further supporting its a role primarily as a coactivator (Chen et al., 2003). 
Similar observations have been made regarding TDG’s role in Wnt signaling.  Wnt 
signaling underlies many fundamental biological processes during embryogenesis and 
importantly, is often dysregulated in cancers.  In colorectal cancer (CRC) aberrant Wnt 
signaling drives proliferation and progression of the disease (Xu et al., 2014). TDG forms 
a complex with CBP and TCF4, a transcription factor critical to Wnt signaling that localizes 
to Wnt-targets and potentiates Wnt-signaling.  ChIP assays at c-myc, in conjunction with 
shRNA-mediated depletion of TDG, revealed that TDG binding is concomitant with H3 
acetylation (a function of CBP/p300) at the site which was not observed upon TDG 
depletion (Xu et al., 2014).  These findings suggest that TDG facilitates transcriptionally 
favorable alterations to the chromatin environment through its recruitment of CBP/p300 to 
Wnt targets. Similar to previous reports, a catalytically inactive mutant of TDG had no 
effects on TDG’s ability to drive Wnt signaling, again supporting the notion that TDG’s 
functionality is primarily that of a scaffold in certain contexts. 
Further work characterizing the functional role of TDG has found using mouse knockout 
models, where TDG knockout is embryonic lethal (Cortázar et al., 2011; Cortellino et al., 
2011).  Interestingly, one group found that Tdg knockout mice exhibited phenotypes that 
resembled both that of CBP/p300 null mice embryos as well as those deficient in select 
RAR/RXR genes, suggesting that TDG deletion may disrupt CBP/p300-mediated and/or 
retinoic acid signaling critical to proper development.  TDG null mice have severe defects 
in both CBP/p300 and RAR/RXR-dependent transcriptional activity. Furthermore, it was 
shown that TDG is responsible for mediating the interaction between RAR/RXR and 
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CBP/p300 and that deletion of TDG prevented CBP/p300 recruitment to RAR/RXR 
targeted genes and also resulted in a loss of H3 acetylation(Cortellino et al., 2011; Hassan 
et al., 2017). Work by a separate group found that in addition to disrupting CBP/p300 
binding at known RAR/RXR sites, TDG deletion disrupted CBP/p300 recruitment at 
various other loci important for development. In addition to disruption of CBP/p300 
recruitment, TDG deletion disrupted recruitment of other important factors including 
GADD45a, AID and MLL1(Cortázar et al., 2011).  
Interestingly, disrupting the glycosylase activity of TDG in mouse models is also 
embryonic lethal (Cortellino et al., 2011). While it is not entirely clear why this occurs, 
TDG’s glycosylase activity has been previously shown to be important for mediating 
RAR/RXR-mediated transcription. RAR/RXR target genes have been shown to have 
methylated promoters to which TDG is recruited, suggesting that in cases whether active 
demethylation of a promoter is required for gene specific transcription, TDG’s glycosylase 
activity becomes essential. 
Finally recent studies have shown that TDG is important for maintaining enhancers in a 
hypomethylated state in embryonic stem cells (Raiber et al., 2012; Wheldon et al., 2014). 
This is important as enhancers can be transcribed to produce long non-coding RNA and 
importantly, these enhancer RNA’s can have functional effects on gene-targets, sometimes 
hundreds of thousands of base pairs away.  While TDG’s role in transcriptional activation 
is well established at promoters, whether or not TDG plays a role in the transcription of 
eRNA at enhancers has not yet been investigated.   Taken together, TDG’s role as a 
coactivator plays a central role in its ability to mediate a diverse set of signaling pathways, 
however the mechanism(s) remain unclear. 
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1.4 Rationale  
To expand the body of knowledge surrounding TDG I explored its role in two systems: 
ERα mediated signaling in the context of the MCF7 breast cancer line, and cellular 
senescence in the context of healthy tissue.  
The steroid hormone receptor ERα is overexpressed in many breast cancers and is often 
the target of endocrine therapies, such as tamoxifen. Importantly, TDG interacts with ERα 
and potentiates its action in a ligand-specific manner (Chen et al., 2003). In the classical 
mechanism of ERα function, ERα is found mainly in the cytosol and binding of ligand 
causes a conformational change that is concomitant with ERα dimer formation and 
translocation into the nucleus. Activated ERα can bind DNA directly through its interaction 
with ERE’s, or the binding can be indirect and mediated through an interaction with various 
transcription factors.  Work focusing specifically on the TFF1/PS2 gene promoter, a well-
studied target of ER-mediated signaling, has found that, in addition to the recruitment of 
ER, E2 treatment resulted in the recruitment of large number of proteins to the TFF1 
promoter that includes histone acetyl transferases and histone methyl transferases, the 
nucleosome remodeling complex SWI/SNF and general transcription factors (Métivier et 
al., 2003, 2008). Experiments which examined the kinetics of cofactor binding revealed 
that rather than binding simultaneously, the recruitment and release of coactivators was 
both combinatorial and cyclical in nature, with certain “sets” of factors binding while 
others released, repeatedly (Métivier et al., 2003). In addition to the previously mentioned 
factors, the promoter of TFF1 underwent cyclical methylation/demethylation during 
transcriptional activation.  Importantly, the increase in methylation coincided with an 
increased binding of DNMT1 while demethylation coincided with release of DNMT1 and 
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binding of TDG.  siRNA mediated depletion of TDG resulted in an inability to effectively 
remove the methylation and prevented TFF1 transcription (Métivier et al., 2008). The 
cyclical methylation and demethylation is concomitant with binding of various cofactors 
and chromatin remodelers, including TDG. Remarkably, knockdown of TDG using siRNA 
resulted in a hypermethylation of the promoter and the inability to induce TFF1 using E2, 
highlighting its critical importance in ERα signaling.  
Recent high-throughput studies have provided a more global picture of E2-dependent ERα 
binding.  One surprising result from these studies was that a substantial portion of ERα 
binding occurred at distal regulatory regions containing histone modifications that mark 
enhancer sites (H3K27ac and H3K4me1). Studies employing GRO-Seq, which identifies 
nascent transcription genome-wide, found that ERα was localized to the enhancers of 
approximately ~90% of genes that showed upregulation in response to E2 (in contrast to 
only ~9% that showed binding of ERα at their promoters) (Li et al., 2013).  
While enhancers are often located in non-coding regions, in response to E2 the majority 
(~83%) of enhancers associated with E2-regulated genes are transcribed. At the time it was 
unclear whether transcription of eRNA was transcriptional noise due to the presence of 
RNA Pol II or played a functional role.  However recent studies have shown that eRNAs 
per se may be required for target-gene transcription in different contexts (Hsieh et al., 2014; 
Li et al., 2013; Melo et al., 2013). ChIA-PET is a technique capable of identifying long-
distance chromatin interactions. These studies revealed that in response to E2, chromatin 
rearrangement surrounding ER-dependent genes occurred by bringing into proximity 
target-gene promoters with enhancers, which often times contain transcription factors, 
coregulators and RNA Pol II, potentiating transcription of the target gene. Importantly, 
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eRNA production at enhancers was shown to mediate this looping (Li et al., 2013). While 
the mechanism through which eRNA regulates 3-dimensional re-organization is still 
unclear, eRNA has been shown to directly recruit chromatin coactivators that may take part 
in promoter-enhancer complex formation (Bose and Berger, 2017). 
Generally, eRNA production often occurs at enhancers that are TET occupied and 
hypomethylated (Pulakanti et al., 2013).  This is interesting, as recent work in mouse 
embryonic stem cells has shown that TDG localizes to enhancers and functions to maintain 
them in a hypomethylated state. Furthermore, eRNA production drives 3-dimensional 
reorganization that mediates ER-dependent transcription and I have recently found that 
TDG mediates similar 3-dimensional reorganization during RAR signaling (Hassan et al., 
2017).  While TDG’s ability to regulate ERα signaling has been established through 
reporter assays as well through targeted assays at specific genes (i.e. TFF1), its role 
globally remains to be explored.   
The second component of my research focuses on the role of TDG in cellular senescence.  
Senescence is a state of persistence cell-cycle arrest that occurs when cells have exceeded 
their proliferative capacity. Proliferative senescence is a complex damage response 
mechanism resulting from telomere depletion and causes an upregulation of cell-cycle 
inhibitors and down regulation of pro cell-cycle signals(Rayess et al., 2012).  In addition 
to exceeding proliferative capacity, cells can be induced to senesce by exposure to ultra-
violet radiation, oxidative stress as well as oncogene expression.  The senescence program 
is a critical barrier to cancer. Senescing cells have distinctive features that distinguish them 
from their healthy counterparts.  Most obvious is a distinct, flattened, morphology and an 
enlarged cytoplasm.  These cells will stain blue when exposed to X-gal under acidic 
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conditions due to an enlarged lysosome cavity and abundance of beta-galactosidase 
enzyme (Kurz et al., 2000).  Transcriptionally, senescing cells often overexpress the tumor 
suppressors p53, p21, ARF and CDKN2A (Chen et al., 1998a). 
CDKN2A and ARF are potent tumor suppressors that are found at the INK4 locus (in 
conjunction with a third tumor suppressor CDKN2B and the long non-coding RNA, 
ANRIL).  Importantly, the transcription of gene-products at this locus sensitive to 
epigenetic regulation: Specifically, methylation of their promoters.  In many cancers the 
promoters of these genes are hypermethylated, and demethylation causes re-expression.  
For example, CDKN2B transcription, which is silenced through promoter methylation, can 
be activated by TGFβ which, in certain contexts, removes promoter methylation 
(Thillainadesan et al., 2012).  Importantly, TDG has been shown to be a critical component 
of the active demethylation process at this promoter, and loss of TDG results ablates 
TGFβ’s ability to induce demethylation of the CDKN2B promoter and its transcription.  
Similarly, reporter assays have revealed that when CDKN2A is hypermethylated, TDG is 
required for its active demethylation and expression(Hu et al., 2010). 
 
1.5 Objectives  
To investigate the mechanism through which TDG regulates transcription, I treated the 
MCF-7 breast cancer cell line with E2, an ERα agonist, and performed ChIP-Seq using an 
antibody specific for TDG to map the locations to which it localizes (Chapter 2).  
Bioinformatic analysis was performed to characterize (A) the binding sites of TDG genome 
wide relative to genomic annotation (B) the overlap between ERα and TDG (C) the overlap 
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between known transcription factors from the ENCODE database and (C) the histone 
marks at these sites.  Based on this analysis I hypothesize that in response to E2 TDG 
regulates ER-target gene transcription through its recruitment to enhancers where it 
mediates the transcription of eRNA and 3-dimensional organization.  To test the 
hypothesis, I performed siRNA mediated knockdown experiments in conjunction with 
real-time qPCR at both target-gene mRNA levels and enhancer eRNA levels from the same 
set of ER-target genes.  Chromosome Conformation Capture (3C) was performed at 
GREB1, a well-studied ERα target gene, to determine whether TDG impacted 3-
dimensional organization.  Finally, using both siRNA-depletion and CRISPR-knockout 
cells, I investigated and characterized the role of TDG in proliferation, adhesion, migration 
and invasion in the context of MCF-7 breast cancer cells. 
In chapter 3, I investigate the role of TDG in senescence in the context of development and 
in human adult fibroblasts.  To determine the role of TDG in senescence I depleted human 
lung fibroblasts of TDG using siRNA and treated them with sublethal, senescence-
inducing, levels of hydrogen peroxide and monitored proliferation using growth curves and 
CDKN2A induction using western blotting.  To delineate a potential mechanism through 
which TDG regulates CDKN2A, I interrogated the methylation status of the CDKN2A 
promoter and performed ChIP using an antibody specific to CBP in the presence and 
absence of H2O2. 
TDG knockout is embryonic lethal, with mice dying at approximately E11.5.  Interestingly, 
recent work has revealed that during development in mice a highly regulated senescence 
program is initiated, and specific structures being undergoing senescence around the time 
knockout TDG mice die.  As no previous study has been published examining the role of 
40 
 
 
 
TDG in developmental senescence, I generated TDG knockout embryo’s and performed 
beta-galactosidase staining and conducted a double-blind study to determine whether TDG 
is important for execution of the embryonic senescence program in mice.  Finally, to 
identify genes affected by TDG knockout I performed RNA-Seq and bioinformatic analysis 
on wildtype and TDG KO embryos.  
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Chapter 2. Genome-wide Analysis Reveals a Role 
for TDG in Estrogen Receptor-mediated Enhancer 
RNA Transcription and 3-Dimensional 
Reorganization. 
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2.1 Introduction 
Steroid hormones such as 17β-estradiol (E2) coordinate complex gene programs and exert 
profound effects on cell growth, development and homeostasis(Farooq, 2015).  E2 
mediates its biological effects by binding to, and activating, the estrogen receptor (ERα 
and ERβ). The ERs are members of the nuclear hormone receptor superfamily which 
function as ligand-activated transcription factors. In the classical mechanism of hormone 
action, E2 binding induces receptor dimerization which facilitates binding to genomic 
DNA at specific sequences in the regulatory region of ERα responsive genes called 
“estrogen response elements”. Importantly, ligand-bound ERα undergoes a conformational 
change that facilitates the recruitment of coactivator proteins that coordinate specific 
transcriptional responses.  
Genome-wide studies using ChIP-based technologies have shown that the majority of ERα 
binding sites in breast cancer cells are found distally from gene promoters, and a significant 
component are found within gene-specific “enhancer” regions in response to E2 (Jin et al., 
2015). Enhancers are essential regulatory regions found in non-coding regions that control 
temporal and tissue-specific gene expression. Furthermore, given that less than 2% of the 
mammalian genome accounts for protein-coding genes, an increasing number of mutations 
and aberrant methylation patterns associated with breast cancer have been found to reside 
in enhancer regions (Aran and Hellman, 2013). In addition to recruiting specific 
transcription factors enhancers also bind specific coregulators and components of the 
transcriptional machinery, including RNA polymerase II. Importantly, some enhancers are 
actively transcribed into long non-coding RNAs known as enhancer RNAs (eRNAs)(Li et 
al., 2013). While the exact role of eRNAs remains controversial, some eRNAs have been 
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shown to regulate gene expression by causing a 3-dimensional conformational change 
bringing together the promoter, enhancer, and transcriptional machinery into 
‘transcriptional pockets’ (Hsieh et al., 2014; Li et al., 2013). It has been shown that E2 
rapidly increases eRNA production at many sites of ERα binding and results in the 
activation of adjacent genes (Li et al., 2013). Although the exact mechanism governing 
eRNA transcription is unclear, recent evidence suggests that enhancer methylation status 
may play a role in eRNA production (Pulakanti et al., 2013). 
DNA methylation occurs at the C5 position of cytosine (5mC) and is found primarily in a 
cytosine-guanine (CpG) context. Genome wide patterns of CpG methylation are deposited 
by the DNA methyltransferases (DNMTs) and are important for the establishment of 
proper chromatin states that are associated with normal development and cellular 
homeostasis (Smith and Meissner, 2013). 5mCs function as targets for methyl-binding 
domain proteins which can subsequently recruit additional chromatin remodelers and co-
repressors (Moore et al., 2013). Furthermore, in a promoter context, methylated CpGs can 
render the site inaccessible to the transcriptional machinery resulting in transcriptional 
silencing. Interestingly, while the majority of genomic DNA is methylated at CpGs 
(Ehrlich et al., 1982), 40-70% of gene promoters contain long stretches of CpG clusters 
(CpG islands) that are unmethylated based on bisulphite sequencing analysis (Saxonov et 
al., 2006). This pattern of global hyper-methylation and promoter hypo-methylation is 
present in healthy tissue and in differentiated cell types. Importantly, improper control of 
the setting and erasure of these marks has been implicated in various pathological 
phenotypes, such as cancer and abnormal embryogenesis (Baylin and Herman, 2000; Haaf, 
2006). 
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Whereas the mechanism of DNA methylation is well understood, a unifying mechanism 
for DNA demethylation has not been unequivocally identified. DNA demethylation may 
occur passively when newly synthesized DNA strands remain unmethylated during 
successive rounds of DNA replication, as a result of DNMT1 inhibition. In contrast, active 
demethylation is a replication-independent process involving the DNA glycosylase 
Thymine DNA glycosylase (TDG).  In one scenario, cytidine deaminases such as 
activation-induced deaminase (AID) or Apolipoprotein B mRNA editing enzymes 
(APOBEC 1-4) convert 5mC to thymine, generating a G:T mispair (Suspène et al., 2005).  
Excision of mispaired thymine by TDG initiates the base excision repair pathway (BER) 
which effectively restores unmethylated cytosine.  However, this model has been 
challenged recently because AID/APOBEC members are much less active on 5mC and its 
derivatives in vitro and in vivo (Nabel et al., 2012). A more plausible mechanism involves 
the Ten Eleven Translocation (TET 1-3) enzymes which oxidize 5mC to 5-
hydroxymethylcytosine (5hmC). Subsequently, 5hmC is then metabolized further by TETs 
into 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) (Ito et al., 2011). These 
oxidized 5mC metabolites, 5fC and 5caC, are recognized and removed by TDG 
(Hashimoto et al., 2013; Maiti and Drohat, 2011).  In addition, an alternative mechanism 
has been postulated for ER-dependent demethylation in breast cancer cells(Periyasamy et 
al., 2015).  ER-dependent transcriptional activation at the TFF1 promoter requires cyclic 
patterns of methylation and demethylation, that is mediated by recruitment of TDG in 
concert with DNMT 3a and 3b (Métivier et al., 2003, 2008). It has been postulated that 
Dnmt3a/b in addition to catalyzing de novo DNA methylation, can facilitate demethylation 
by deaminating 5mC when SAM levels are limiting (van der Wijst et al., 2015).  
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The generation of TDG knockout mice has corroborated the importance of TDG in 
regulating active demethylation and tissue specific gene expression. Deletion of TDG in 
the germline is embryonic lethal and leads to DNA hypermethylation and defects in the 
expression of various developmentally regulated genes (Cortázar et al., 2011; Cortellino et 
al., 2011)  Additionally, 5fC and 5caC levels increase five to ten fold genome wide in TDG 
null ES cells (Wu et al., 2014), (Song et al., 2013). TDG has also been implicated in 
transcriptional control and gene expression by functioning as a molecular scaffold protein.  
TDG  interacts directly with ERα in a ligand dependent manner and co-localizes to the 
promoter of TFF1 (Chen et al., 2003) resulting in increased gene expression, effects which 
are lost when TDG is depleted (Métivier et al., 2008).  TDG also interacts directly with 
other transcription factors  and coregulators and in TDG null MEFs, the presence of TDG 
is required for recruiting the acetyltransferases CBP/p300, TET2 and other histone 
modifying enzymes to a subset of target genes (Cortázar et al., 2011; Cortellino et al., 2011; 
Hassan et al., 2017; Tini et al., 2002). These findings are consistent with the notion that 
TDG plays a central role in epigenetic stability and methylation control.  
In this study, I generated a global profile of TDG binding in MCF7 breast cancer cells in 
response to E2 treatment using ChIP-Seq. I have integrated the data from our ChIP-Seq 
assays with data from other genomic assays to provide a global view of TDG binding. In 
response to E2 treatment, I show that TDG binds primarily to genomic regions upstream 
of target genes which, in addition to recruiting ERα and RNA Polymerase II, also bind 
various transcription factors, co-regulators and epigenetic modifiers including p300, 
GATA3 and Tcf7l2 and are marked by histone marks indicative of active enhancers. 
Importantly, TDG binds to regions which, in response to E2, transcribe eRNAs and take 
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part in 3-dimensional restructuring of the genome.  Remarkably, at a subset of enhancers 
that E2 targets, I found that TDG depletion abrogates E2-mediated eRNA, disrupts 3-
dimensional reorganization at ERα targets such as GREB1 and disrupts E2-mediated 
transcription of corresponding ER-target genes.  To investigate whether TDG plays a 
functional role in E2 signaling in breast cancer, I engineered an MCF7 TDG-knockout cell 
line using CRISPR technology and found that TDG knockout and depletion leads to defects 
in E2 mediated proliferation and sensitizes MCF7 cells to the anti-estrogen, tamoxifen. 
Importantly, I also find that TDG depletion causes adhesion defects and drastically 
increases the migratory capacity and invasiveness of MCF7 cells.  Collectively our findings 
suggest that TDG plays a central role in mediating the transcriptional and functional effects 
of E2 in breast cancer and may prove to be an effective therapeutic target. 
 
2.2 Results 
2.2.1 Global TDG binding in response to E2 
Previous reports have shown that, in response to E2, TDG physically interacts with ERα 
and localizes to TFF1/PS2, a well characterized ER-target gene(Métivier et al., 2008). To 
determine whether colocalization of TDG and ERα extends to other genomic locations, 
MCF7 cells were treated with 100 nM E2 for 45min and ChIP-Seq was performed using a 
TDG-specific antibody. Biological replicates were performed and for each replicate the 
reads were processed to remove duplicates and corrupted reads before being mapped to the 
human genome (hg19). Areas of significant enrichment were identified using an FDR 0.01. 
To identify only high confidence peaks, the peak set was filtered and only those peaks with 
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a p-value < 0.05 and fold-change greater than 1.2-fold were retained. Finally, by retaining 
only peaks which appeared in both biological replicates I was able to identify 117 highly-
confident regions to which TDG localized in response to E2.  Validations were performed 
using conventional ChIP-qPCR (Figure 2-1A). Compared to genomic background, global 
analysis of the high-confidence TDG peaks revealed that E2-dependent TDG binding was 
enriched at promoters (7% of total TDG peaks, compared with 3% genomic background) 
as well as distal to promoters with approximately 60% occurring intergenically (compared 
to 52% for background) (Figure 2-1 B). However, overlapping TDG peaks with sites of 
E2-dependent ERα localization revealed that 45% of TDG peaks occur at the same sites 
where ERα localizes in response to E2 (Figure 2-1 C and D). 
Recent studies have shown that the ERα is found at enhancers and colocalizes with various 
transcription factors known to play important roles in enhancer regulation (Nguyen et al., 
2014). The publicly available database, “Transcription Factor ChIP-Seq Uniform Peaks” 
from ENCODE contains the binding profiles of these and other transcription factors from 
numerous cell lines. I compared E2-dependent TDG binding to the 690 files available from 
ENCODE using two measures of similarity: Jaccard statistic and the Fisher exact test. 
Within the ENCODE datasets, those which most closely resemble E2-dependent TDG 
binding are the datasets from experiments recording ERα binding in response to E2  
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Figure 2-1. Global analysis of E2-dependent TDG localization. 
(A) MCF7 cells were treated with 100nM of E2 (45min) and ChIP-qPCR was performed 
using TDG antibody. Region used as negative control shows low level of TDG binding in 
ChIP-Seq data with no change in levels after E2 treatment. (*p-value < 0.05, error bars 
represent standard deviation of the mean, n>2). (B) Sites of E2 dependent TDG binding 
were mapped to the annotated genome using CEAS (C) Venn diagram showing overlap 
between E2-dependent TDG peaks and ERα peaks obtained from public dataset. (D) Sites 
of ERα binding (-/+ 1000bp) overlaid with TDG binding signal, showing strong 
relationship between location of TDG binding and ERα binding at these regions.   
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treatments in breast cancer cells such as MCF7 cells and the metastatic T-47D breast cancer 
cell line.  The other transcription factors that exhibit binding patterns most similar to that  
of TDG are p300, GATA3, Tcf7l2, the oncoprotein ZNF217, and RNA polymerase II 
(Figure 2-2A and B). Importantly, these proteins have been identified as having important 
roles at enhancers. Interestingly, I also observe higher similitude between TDG and both 
Myc and E2F1.  While both proteins have been implicated in breast cancer progression, 
little is known concerning their respective roles at specific enhancers.  Motif analysis 
focusing on TDG peaks that overlap with ERα revealed an enrichment for the canonical 
Estrogen Response Element motif, as well as the GATA DNA binding motif (Figure 2-
2C).  In contrast, TDG peaks that do not overlap with ERα are enriched for only a single 
motif, PU.1. Transcription factors from the GATA family regulate genes that are 
implicated in cell cycle arrest and cell survival (Zheng and Blobel, 2010). GATA3, 
specifically, has been identified as a critical component of mammary epithelial cells 
development and is 1 of 3 genes that have been shown to be mutated in >10% of breast 
cancers (Theodorou et al., 2013). Furthermore, GATA3 has been shown to mediate 
enhancer accessibility in MCF7 cells and its depletion results in an altered binding profile 
of ERα upon E2 treatment, with a corresponding altered change in target gene expression 
(Theodorou et al., 2013).  
Distal regulatory sites involved in gene repression or activation are frequently marked by 
specific histone modifications.  Enhancers involved in transcriptional activation high levels 
of H3K27Ac, H3K4me2 and H3K4me3 (Chen et al., 2015; Creyghton et al., 2010; Lupien 
et al., 2008) while sites involved in silencing are often devoid of most of these marks and 
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instead contain H3K9me3 and H3K27me3 (Zentner et al., 2011; Zhu et al., 2012). To gain 
a better understanding of the epigenetic makeup of sites to which TDG localizes in 
response to E2, I compared our data with that of publicly available ChIP-Seq datasets 
performed using antibodies against histone modifications. Aggregate plots and heatmaps 
at sites of TDG, or TDG and ER, localization in response to E2 revealed that TDG localizes 
with histones containing marks found at active enhancers (H3K27Ac, H3K4me2 and 
H3K4me3) and depleted almost entirely of histone markings corresponding to repressed or 
silenced enhancers (H3K9me3 and H3K27me3) (Figure 2-2D and E).   
To determine the extent of overlap of TDG and the transcription factors identified in our 
global analysis, I cross-referenced genes whose transcription is induced upon E2 treatment 
with genes that are adjacent to TDG peaks (-/+ 100kb) to identify E2-inducible genes that 
are potentially regulated by TDG. A subset of genes meeting these criteria were selected 
and a closer examination of the genomic landscape surrounding sites of TDG was 
performed (Figure 2-3).  Remarkably, I find highly-enriched binding occurs precisely at 
sites which bind the transcriptional factors identified in our original ENCODE analysis.  
Furthermore, these sites of E2-dependent TDG localization are enriched for histone marks 
that correspond to active enhancer while being devoid of marks corresponding to 
repressed/silenced enhancers, predicted by our previous bioinformatic analysis (Figure 2-
2D and 2-2E).  I also found a basal-level of TDG binding across the DNA at these regions 
which is likely reflective of TDG’s non-specific DNA binding activity. 
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Figure 2-2. TDG localizes to sites occupied by transcription factors. 
(A) Individual datasets obtained from the Transcription Factor ChIP-Seq Uniform Peaks 
dataset from ENCODE were compared to the TDG dataset using the Fisher exact test p-
value and Jaccard statistic to determine relative similarity. A subset of the most similar 
matches is labelled with the cell type and treatment, if disclosed, in brackets (B) Overlap 
between TDG peaks and the corresponding ENCODE dataset (The average binding profile 
of the 10 least similar datasets from the ENCODE database was used as controls. None of 
the 10 least similar had more than a single peak which overlapped with our dataset). (C) 
Motif analysis performed on sites of E2 mediated TDG localization revealed the canonical 
estrogen response element (ERE) as a top hit followed by GATA protein consensus binding 
site. (D) Overlap of ChIP-Seq signal from publicly available histone datasets at sites of E2-
dependent TDG binding in MCF7 cells. (E) Heatmaps showing intensity of histone marks 
at sites of TDG binding.  Sites where TDG localizes in response to E2 are enriched for 
histone marks indicating ‘active’ enhancers (H3K27Ac, H3K4me2 and H3K4me3) while 
depleted for those marking ‘repressed’ enhancers (H3K9me3 and H3K27me3). 
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Figure 2-3. Transcription factor binding and histone modifications at a subset of 
TDG-targeted genes. 
Genomic regions surrounding genes identified as having E2-dependent TDG binding and 
increased transcription show precise overlap of TDG, ERα and a subset of ENCODE 
transcription factors. Additionally, overlap with datasets containing histone ChIP-Seq data 
reveals the enrichment of histone marks corresponding to active/poised enhancers and 
depleted of those marking repressed/silenced enhancers (SM = standard media).  
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2.2.2 TDG depletion disrupts E2 mediated transcription of ERα 
target genes 
Due to its role as a transcriptional co-activator, I sought to determine whether genes to 
which TDG binds, in response to E2, are up- or down-regulated. To address this, I  
identified genes adjacent to TDG binding sites and then obtained their transcriptional 
response to E2 from publicly available data (Putnik et al., 2012).  I find that genes which 
are differentially expressed in response to E2, and to which TDG localizes, are most often 
up regulated and the magnitude of change is significantly higher in genes that are 
upregulated when compared to those that are down regulated (Figure 2-4A and B). To 
determine whether TDG is critical to the E2-dependant changes in expression, I first treated 
MCF7 cells with siRNA targeting TDG and immunoblotted for TDG and ERα to ensure 
ERα levels remained stable during TDG depletion.  I then treated MCF7 cells previously 
treated with scrambled siRNA or siRNA targeting TDG with 100 nM E2 for 1hr and 
measured mRNA levels of a subset of target genes using qPCR.  Remarkably, I find that 
TDG depletion does not affect levels of ER, yet significantly reduces E2-mediated increase 
in the transcript levels of all ERα dependent target genes tested. (Figure 2-4C and D).   A 
look at the top 10 genes that bind both TDG and are expressed upon E2 treatment reveals 
a slight correlation between magnitude of TDG binding and gene expression (Figure 2-
4E). 
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Figure 2-4. TDG is required for E2 dependent gene expression. 
TDG peaks were mapped to genes using GREAT software and cross-referenced with 
publicly available MCF7 E2-dependant expression data.  (A) Most genes associated with 
TDG binding undergo up-regulation in response to E2 and (B) the fold-change experienced 
by up-regulated genes in response to E2 is greater in magnitude than the fold-change 
experienced by down-regulated genes (box-and-whisker plot).  (C) Western blot of TDG 
and ERα levels after treatment with scrambled siRNA (siControl) or siRNA targeting TDG 
(siTDG) (left panels).  (D) To determine whether TDG was important for transcriptional 
upregulation of these genes, siControl or siRNA targeting TDG were treated with 100 nM 
E2 for 1h.  Analysis of mRNA levels using qPCR revealed that loss of TDG decreases, and 
in some cases completely abrogate, E2-mediated transcription (n=3, p-value < 0.05).  (E) 
Comparison of E2-mediated TDG binding at genes which also experience the greatest 
increase in E2-mediated transcription (Spearman coefficient shown). 
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2.2.3 TDG is required for eRNA production 
Recent studies using Global Run-On Sequencing (GRO-Seq) characterized nascent 
transcription in response to E2 treatment in MCF7 cells and showed that many of the ERα 
bound enhancers bind RNA pol II and transcribe enhancer RNAs (eRNA)(Li et al., 2013). 
Importantly, eRNA transcription and/or eRNA transcripts per se are required for activation 
of adjacent target genes(Li et al., 2013). To determine whether TDG plays a role in eRNA 
transcription, I first looked too see whether sites of TDG binding coincide with sites of E2-
mediated eRNA transcription in MCF7 cells by overlaying sites of E2 dependent TDG 
localization with publicly available GRO-Seq data.  I find that, on average, sites of E2-
dependent TDG localization also undergo a concomitant increase in transcription in 
response to E2 (Figure 2-5A and B).  Furthermore, sites of TDG binding at the enhancers 
of target genes I examined previously, overlap precisely with locations that undergo 
transcription at those targets (Figure 2-5C). Transcription of non-coding RNA from ER-
targeted enhancers is readily induced by 100 nM E2 treatment for 1hr. Remarkably, 
depleting TDG protein using siRNA prior to treatment abrogates the ability of E2 to induce 
eRNA from TDG-targeted enhancers (Figure 2-5D). These findings reveal for the first time 
a potential mechanism by which TDG regulates ER-signaling. 
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Figure 2-5. TDG depletion impacts eRNA production. 
(A) Publicly available GRO-Seq data looking at levels of transcription at sites of E2-
dependent TDG binding reveals that sites of TDG binding experience increase in 
transcription in response to E2 (a set of random peaks reflecting precisely the size 
distribution of actual TDG peaks was used as control). (B) Heatmap of nascent 
transcription using publicly available GRO-Seq data at sites of TDG -/+ E2.  (C) E2 effects 
on localization of TDG and ER, as well as transcription response, at specific targets.  (D) 
To determine whether TDG is required for eRNA production, MCF7 cells were depleted 
of TDG using siRNA and transcript levels were measured in response to 100nM of E2 (1h) 
(qPCR, p-value < 0.05).  
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2.2.4 TDG is required for 3D conformational changes  
Recent work in both ERα and androgen-receptor mediated signaling has revealed that 
eRNA transcription and/or eRNA transcripts facilitate 3-dimensional re-organization of the 
genome bringing the enhancer regulatory region into proximity with the promoter and 
activating optimal target gene transcription (Hsieh et al., 2014; Li et al., 2013). Chromatin 
Interaction Analysis by Paired-End Tag sequencing (ChIA-PET) is a technique used to 
capture and quantitate long-range chromatin interactions that occur in the presence of a 
protein of interest. By comparing ER-dependent TDG binding  to data obtained from ChIA-
PET looping that occurs at sites of ERα binding in MCF7 cells, I find that a large 
component of E2-mediated TDG binding occurs precisely at genomic sites that are 
involved in the interactions between promoter and enhancer (Figure 2-6 A and B). Previous 
groups have reported that eRNA production at GREB1 is a critical mediator of long-range 
looping and targeted eRNA degradation is itself enough to attenuate looping and enhancer-
complex formation at this gene (Figure 2-6C) (Li et al., 2013). Based on our findings that 
TDG depletion inhibits E2 driven production of eRNA at GREB1, I predicted that TDG 
depletion may negatively impact the long-range loop formation. To explore this possibility, 
I induced formation of looping at GREB1 by treating cells with 100 nM E2 for 1hr after 
siRNA-mediated depletion of TDG.  Similar to previous reports I find that E2 is able to 
induce the formation of the enhancer-promoter loop at GREB1. Remarkably, ERα 
continues to be recruited to enhancer in the absence of TDG (Figure 2-6D), but 3D 
reorganization is abrogated when TDG is depleted, highlighting TDG’s impact not only on 
eRNA production but also on 3-dimensional chromosomal rearrangement (Figure 2-6E).  
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Figure 2-6. TDG peaks overlap with sites involved in promoter-enhancer looping. 
TDG binding was compared to public datasets containing E2-dependent ERα localization 
and ChIA-PET performed using an antibody against ERα.  (A) Heatmap showing ChIA-
PET signal at sites of TDG binding (left) and aggregate plot showing global average (right). 
(B) Overlap of TDG, ER, and ChIA-PET signal at specific sites reveals TDG, ERα and 
looping occur at precisely the same locations at these sites. (C) Schematic of GREB1 
showing approximate locations of looping as identified by publicly available data.  (D) 
ChIP using ERα in the presence and absence of TDG as well as – or + E2, showing that 
ERα binding is unaltered during depletion of TDG. (E) Loss of TDG prevents enhancer-
promoter looping at the GREB1 locus.  MCF7 cells were treated with siControl or siTDG, 
and then treated with 100 nM E2 for 1hr.  3C, semi-quantitative method of measuring the 
looping between the GREB1 enhancer and promoter, revealed that E2 driven looping of 
the enhancer and promoter is disrupted upon TDG knockdown. 
  
83 
 
 
 
 
 
84 
 
 
 
 
2.2.5 Methylation status is not impacted by TDG knockdown 
Recent studies have shown that  the 5mC derivatives 5caC and 5fC,  generated during 
active demethylation, accumulate at ‘open’ enhancers in TDG knockout MEFs (Raiber et 
al., 2012; Song et al., 2013) suggesting that active demethylation may be important for  
eRNA production. Comparing sites of E2-dependent TDG binding with publicly available 
bisulphite sequencing and DNase data revealed that while TDG binding coincides with 
‘open’ genomic regions, the CpG’s are not methylated and the regions are in an ‘open’ 
state (Figure 2-7A-C) (Menafra et al., 2014). Bisulfite sequencing is unable to distinguish 
between unmethylated cytosine and 5fC/5caC.  To obtain a clearer picture of what impact 
E2 signaling and TDG may have on 5mC derivatives at enhancers, I performed Methylase-
assisted bisulfite sequencing (MAB-Seq). MAB-Seq consists of pre-treating genomic DNA 
with the bacterial methyltransferase enzyme M.SssI, which methylates unmodified 
cytosines (C). The M.SssI treated DNA is then treated with bisulphite which converts 5fC 
and 5caC to thymine (T) but does not convert cytosines (which have been converted 
upstream to 5mC by M.SssI). Therefore, sequencing would indicate 5fC and 5caC as T, 
whereas C/5mC/5hmC would be sequenced as C. Comparing bisulphite sequencing with 
MAB-Seq results confirmed that TFF1 and GREB1 enhancers are composed almost 
entirely of unmethylated cytosines and are not altered either in response to E2 treatment or 
TDG depletion indicating that active demethylation at specific enhancers is not required 
for E2 signaling (Figure 2-7D).   
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Figure 2-7. Cytosines in TFF1 and GREB1 enhancers are epigenetically unmodified. 
 (A) Comparing TDG binding at sites regulated by E2 reveals that TDG binds to 
hypomethylated locations.  (B) Heatmap comparing methylation signal at sites of TDG 
binding globally, reveals that TDG binds to hypomethylated sites.  (C) MCF7 DNase signal 
intensity, revealing that, globally, TDG binding occurs preferentially at sites which are 
hypomethylated and ‘open’. (D) Bisulfite-sequencing and MAB-Seq at TFF1 after cells 
were treated with scrambled siRNA (siControl) or siRNA targeting TDG (siTDG) and then 
with or without E2 treatment. TFF1 enhancer is devoid of any methylation or active-
demethylation metabolites and remains so in response to E2 or TDG depletion.   
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2.2.6 TDG knockdown affects cell proliferation of MCF7 breast 
cancer cells 
Gene Ontology (GO) enrichment analysis was performed on genes which bind TDG and 
are upregulated in response to E2. I found a significant enrichment at GO terms directly 
related to proliferation, including “regulation of epithelial cell proliferation”, as well as 
multiple terms implicating a role in “differentiation” and “Wnt signaling”. Wnt signaling 
was a particularly interesting finding as TDG has recently been shown to directly 
upregulate components of Wnt signaling pathway  in colorectal cancer (CRC), and TDG 
depletion inhibited proliferation of CRC cells both in vitro and in vivo (Xu et al., 2014).  
To determine whether TDG plays a role in E2-dependent cell proliferation I deleted TDG 
from MCF7 cells constitutively using CRISPR technology, or transiently using siRNA 
(Figure 2-8).   In both systems, TDG depletion significantly decreases the E2-mediated 
increase in proliferation compared to control cells, while also increasing sensitivity to the 
anti-estrogen tamoxifen, with TDG depleted cells exhibiting a stronger cytostatic response 
than controls (Figure 2-9A). 
Estrogens and the anti-estrogens, such as tamoxifen, can modulate the proliferation 
capacity of breast cancer cells in part by causing complex rearrangements of both the 
cytoskeleton and adhesion apparatus (DePasquale et al., 1994; Ma et al., 2014; Millon et 
al., 1989). Remarkably, I find that TDG depletion in MCF7 cells drastically alters decreases 
their ability to adhere to the substratum, and to one another (Figure 2-9B and C).  This 
finding is important as anti-estrogens promote an invasive  
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Figure 2-8. CRISPR-mediated deletion of TDG in MCF7 cells. 
 (A) To eliminate TDG protein from MCF7 cells I used the CRISPR/Cas-9 and pair guided 
excision to remove a 490bp region of TDG which contained exon 2 and which also created 
a frame-shift.  (B) Protein levels of TDG in wildtype (WT) cells as well as those edited 
using CRISPR or siRNA (C: control siRNA or non-targeting CRISPR, TDG: siRNA 
targeting TDG or CRISPR targeting TDG). 
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Figure 2-9. TDG depletion sensitizes MCF7 cells to Tamoxifen and produces 
proliferation and attachment deficiencies. 
(A)  Growth curves examining responsiveness of CRISPR-mediated (upper panel) and 
siRNA-mediated (lower panel) TDG knockout and knockdown respectively.  MCF7 cells 
were grown for 48-72h in charcoal-stripped phenol-red free media prior to treatment (left 
panel) (n=3, p-value < 0.05, error bars show -/+ 1 standard deviation).  (B)  To examine 
migration and adhesion MCF7 cells were treated with either scrambled siRNA or siRNA 
targeting TDG and grown in regular media for 2 days prior to performing the cell-to-cell 
adhesion assay. I found that MCF7s with depleted levels of TDG form significantly less 
aggregates with one another (n = 4, error bars indicate standard deviation -/+ 1) (C) 
Treatment of MCF7 cells with varying concentration of Trypsin revealed that those 
depleted of TDG detached from tissue-plate substratum at lower concentrations (top panel) 
and upon resuspension TDG depleted cells demonstrated re-attachment deficiencies, 
remaining loosely attached and spherical while cells treated with siControl became 
stabilized with visible ‘flattening’ indicative of cell-substratum contacts(bottom panel).  
(D)  To measure the effect of TDG on the migration and invasion capacity, TDG was 
depleted in MCF7 cells using siRNA which were treated with or without Tamoxifen for 
3d. Cells were harvested using 3mM EDTA and a suspension of 100,000 cells was 
incubated at 37C for 72 in gelatin or Matrigel to test migration and invasion, respectively.  
Cells were counted using ImageJ (n=4). MCF7s depleted of TDG show a drastically more 
aggressive profile with cells migrating and invading gel at a significantly higher rate than 
siControl cells.   
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phenotype in breast cancer cells which have adhesion deficiencies (Borley et al., 2008).  
Specifically, the researchers found that exposure to tamoxifen or fulvestrant promoted 
invasion in cells maintaining poor cell-cell contacts.  To test whether the adhesion defects 
observed in TDG-depleted MCF7s promote migration or invasion, I depleted TDG in 
MCF7s using siRNA and treated cells with the anti-estrogen tamoxifen and recorded their 
ability to transverse gelatin, or Matrigel, respectively.  While TDG depletion sensitizes 
MCF7 cells to the cytostatic effects of tamoxifen, I find that MCF7 cells depleted of TDG 
become much more aggressive, with significant increases in both migration and invasion 
capacity (Figure 2-9D). 
 
 
2.3   Discussion 
Utilizing a combination of functional genomic analysis and biological assays, I have 
identified a role for TDG in E2 dependent signaling in MCF7 breast cancer cells.  In 
response to E2 TDG localizes to distal regulatory sites of ERα target genes. Approximately 
half of the TDG binding sites identified overlap with sites of E2-mediated ERα binding. 
 Importantly, in response to E2 TDG localizes to enhancer regions that play an important 
role in the production of eRNAs and 3-dimensional re-organization important for target 
gene transcription. By focusing on a subset of TDG target genes whose transcription is 
upregulated in response to E2 treatment, I found that TDG depletion significantly reduces 
the ability of E2 to induce transcription of eRNA produced at the enhancers, disrupts 
looping, and inhibits transcription of the target genes.  
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eRNA producing enhancers have several common characteristics that include increased 
binding of transcriptional coactivators, greater chromatin accessibility and increased 
formation of enhancer promoter looping.  Although a direct functional role of eRNAs is 
still unclear, mounting evidence supports the notion that eRNA production is not merely 
transcriptional noise as previously suggested but play a functional role by contributing to 
transcriptional activation of adjacent coding genes.  While it remains unclear as to whether 
eRNA transcription or the eRNA transcript per se are responsible for 3-dimensional re-
organization that brings the enhancer and promoter into proximity of one another, I have 
found that TDG depletion disrupts gene transcription broadly, interrupting both eRNA 
production, 3-dimensional reorganization and activation of target gene transcription. 
Furthermore, the finding that TDG binding occurs primarily outside of promoters suggests 
that dynamics at enhancers play an important role in regulating ERα target gene expression. 
Previous reports have suggested that stimulation of ERα signaling at some promoters 
triggers a cyclical methylation/demethylation mechanism involving DNMTs (Métivier et 
al., 2003, 2008). It was proposed that in addition to functioning as DNA 
methyltransferases, DNMT3a/b are capable of deaminating 5mC when SAM is limiting.  
The resulting G:T mispair is then excised by TDG and the base excision repair machinery 
restores unmethylated cytosine.  More recently reports have emerged showing that TDG 
depletion in embryonic stem cells resulted in the accumulation of active demethylation 
metabolites 5fC and 5caC at identified enhancer regions (Shen et al., 2013; Wu et al., 
2014). To determine whether active demethylation plays a role at enhancers I used MAB-
Seq to establish a profile of the active demethylation intermediates 5fC/5caC at the site of 
TDG binding pre- and post-E2 treatment and in conjunction with wildtype TDG levels or 
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with siRNA-mediated depletion of TDG.  I found that the TFF1 enhancer appears to be 
composed entirely of unmodified cytosines regardless of E2 treatment.  The observation 
that TDG depletion in MCF7 breast cancer cells leads to no accumulation of 5fC/5caC 
supports reports that the glycosylase activity of TDG is dispensable for E2 mediated 
signaling and instead it is TDGs ability to act as a coactivator that potentiates ERα 
activity(Chen et al., 2003). 
The importance of E2-dependent signaling in breast cancer has been well documented.  For 
example, it has been demonstrated that growth, proliferation and metastatic nature of 
MCF7 cells transplanted into nude mice are E2 dependent (Kubota et al., 1983).  Treatment 
of MCF7s with either E2, or the anti-estrogen tamoxifen, has been shown to cause changes 
in proliferation and growth through complex large-scale rearrangements of the 
cytoskeleton and adhesion apparatus (Borley et al., 2008; DePasquale et al., 1994; 
Marchisio et al., 1986). Based on our findings that TDG seems to be intimately involved 
with E2 signaling I investigated whether its role extends to proliferation.  I found that 
deleting TDG from MCF7 cells using either CRISPR technology or siRNA transfection 
inhibited E2-dependent proliferation. Interestingly, GO analysis revealed that E2 causes 
TDG binding and upregulation of genes involved in “Wnt signaling”, in addition to other 
proliferation-related categories such as multiple GO terms referencing ‘differentiation’.  
This is consistent with previous studies showing that TDG plays a critical role in the 
progression of colorectal cancer by upregulating components of Wnt signaling pathway in 
a CBP/p300 dependent manner. Importantly, researchers observed that TDG depletion 
significantly inhibited proliferation of CRC cells in vitro and in vivo (Xu et al., 2014).  
Taken together, our findings suggest that TDG’s role in Wnt signaling may perhaps extend 
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outside of CRC and play an important role in breast cancer.  Further studies will be required 
to determine to what extent this may be the case. 
We have found that TDG is also critical for maintaining proper cell-cell and cell-
substratum contacts in MCF7 cells and depletion of TDG leads to broad adhesion defects.  
This is an important consideration as tamoxifen treatment has been shown to promote an 
invasive phenotype in ER-positive breast cancers when cell-cell contacts are weak (Borley 
et al., 2008). Migration and invasion assays have confirmed this, revealing that TDG 
depletion results in a much more aggressive phenotype with cells demonstrating drastically 
increased migration and invasion capacity in response to tamoxifen suggesting that TDG 
possesses tumour suppressive properties despite being a positive regulator of estrogen 
dependent cell growth. Based on these opposing roles I would predict that cells containing 
a TDG mutation would not have a selective growth advantage and would be removed 
before causing genetic and/or epigenetic changes resulting in cancer. This may explain why 
homozygous mutations for TDG have not been identified in breast cancer based on TCGA 
data set analysis. Taken together, our findings reveal TDG is important in E2 signaling by 
regulating eRNA production at ER-targeted enhancers.  Furthermore, our functional 
analysis revealed that TDG plays a critical role in proliferation in response to estrogens 
and anti-estrogens.  Further investigation into the potential for TDG as a therapeutic target 
is strongly warranted.  
 
2.4 Materials and methods 
Cells culture, treatment and transfections 
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MCF7 cells were obtained from ATCC and grown in low-glucose DMEM and 10% Fetal 
Bovine Serum (FBS). Prior to treatment, cells were washed once with Phosphate Buffered 
Saline (PBS) and grown in phenol red-free media containing charcoal stripped FBS (10%) 
for 72h. Cells were then washed and treated with 100 nM E2 for specific time periods. 
For siRNA mediated knockdowns, cells were incubated with Lipofectamine 2000 
(LifeTechnologies) and siRNA targeting TDG (Dharmacon, M-040666-01) or scrambled 
siRNA (Dharmacon, D-001210-03) for 24h, media was replaced with fresh media for 48h 
at which point experiments were performed. 
MCF7 CRISPR TDG-/- 
CRISPR TDG-/- and CRISPR TDG+/+ MCF7 cells were generated as previously 
described using wildtype Cas-9 and two cut sites:  
Cut-site 1 (bottom strand): CACCGGTTATTAAGCACTCAGTAA,  Cut-site 1 (top 
strand): AACTTACTGAGTGCTTAATAACC; Cut-site 2 (top strand): 
(CACCGTCTGGGGAATAAAAGAACAT), Cut-side 2 (bottom strand): 
AAACATGTTCTTTTATTCCCCAGAC.  
Primers used for detection: 
Forward(GGCTGACTTGACAGGACTGA), 
Reverse(CTGTGCTGAGCTGTAACGTG)(Hsu et al., 2014).   
Protein extraction 
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Whole cell protein extracts were obtained by harvesting cells in RIPA lysis buffer (50mM 
Tris-pH 8.0, 150mM NaCl, 1% NP-40, 0.1% SDS, and protease inhibitor cocktail), 
incubating on ice for 15min, followed by centrifugation for 15 min at 4°C (20,000 RCF). 
Protein concentrations were normalized and proteins were separated using SDS-PAGE and 
transferred to PVDF membrane. Blocking buffer containing PBS, 0.1% Tween-20 and 5% 
skim milk powder was used for primary and secondary incubation as well as washes. 
Protein of interest was visualized using Luminata Forte Western HRP Substrate (Cat. No. 
WBLUF0100) and by exposure to autoradiography film (GE Healthcare).  
RNA extraction, reverse transcription and qPCR 
RNA extraction was performed using TRI-zol (Ambion) in accordance with the 
manufacturer’s directions, with additional ethanol wash steps as needed. 2μg of total RNA 
was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). mRNA levels were ascertained using pre-designed TaqMan probes (Applied 
Biosystems) targeting the genes of interest, while enhancer RNA levels were monitored 
using custom designed primers spanning the regions of interest and SYBR Green, per 
manufacturer’s instructions. Experiments were performed with technical triplicates and 
biological duplicates and run in a 96-well format using the StepOne Real-time PCR System 
(Applied Biosystems) using GAPDH as a normalization control, unless otherwise noted. 
Sequences of probes are listed in additional files (see Additional file 12). 
ChIP-Seq preparation and analysis 
MCF7 cells were serum starved for 3 days, treated with 100 nM E2 for 45min and then 
ChIP was performed using a polyclonal TDG-targeting antibody that was antigen affinity 
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chromatography purified (Thermo Fisher Cat. PA5-29140), as previously described, with 
minor alterations (Thillainadesan et al., 2012). Briefly, cells were cross-linked using 1% 
formaldehyde in PBS for 10 minutes under shaking at RT. 125 mM glycine in PBS was 
added for 5min to quench the reaction. Cells were then washed twice with ice-cold PBS 
and harvested in 1 ml of ice cold PBS buffer. The cells were then pelleted at 250g for 10 
minutes, washed twice with ice-cold PBS (protease inhibitors added), and then lysed using 
200 μl of lysis buffer (1% SDS, 50 mM Tris-HCl [pH 8.0], 10 mM EDTA, and protease 
inhibitors) for 15 minutes on ice. The cell lysates were then sonicated, and cell lysate was 
centrifuged at 15000 rpm for 15 minutes. An aliquot of the supernatant mixture was saved 
as input DNA, and the remaining lysate was incubated with 5ug of antibody in 50 μl of 
protein A/G dynabeads as per instructions.  Immunoprecipitation was performed overnight 
at 4°C under rotation. After the immunoprecipitation, the dynabeads were washed twice 
using wash buffer I (0.1 % SDS, 1 % Triton X-100, 2 mM EDTA, 20 mM Tris-HCl [pH 
8.0], 150 mM NaCl), once with wash buffer II (0.1 % SDS, 1 % Triton X-100, 2 mM 
EDTA, 20 mM Tris-HCl [pH 8.0], 500 mM NaCl), wash buffer III (0.25 M LiCl, 1% NP-
40, 1% Na-deoxycholate, 1 mM EDTA, 10 mM Tris-HCl [pH 8.0]) and twice with Tris-
EDTA buffer (pH 8.0). The chromatin was eluted using 150 μl of freshly made elution 
buffer I (1% SDS, 0.1 M NaHCO3) twice at 65°C for 10 minutes. NaCl was added to the 
eluates and input DNA to a final concentration of 0.3 M and both were incubated at 65°C 
overnight. Immunoprecipitated DNA was purified using QIAquick PCR Purification Kit 
(Qiagen) and was analyzed by quantitative PCR following ChIP in technical triplicates and 
biological duplicates, unless otherwise noted. For high-throughput sequencing 
immunoprecipitated DNA was sequenced in duplicates at The Centre for Applied 
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Genomics Next Generation Sequencing facility (Toronto, Ontario). Sequenced reads were 
mapped to the human genome (hg19) and Partek Genomic Suite was used to call peaks 100 
bp bins at an FDR of 0.05. Peaks were further filtered, retaining only those peaks which 
appeared in both replicates and which showed a greater-than 1.2-fold increase and had a p-
value < 0.05 in both replicates. 
MAB-Seq 
Methylase assisted bisulfite sequencing was performed according to Zhang Y et al. (2014). 
Briefly, 1 μg of genomic DNA was treated with 4 U of M.SssI in a 20 μl reaction containing 
160 mM of SAM. After 2h, the reaction was supplemented with an additional 4 U of M.SssI 
and 160 mM SAM for an additional 4 hours. This was repeated three times. DNA was 
purified by conventional phenol:chloroform:isoamyl-alcohol extraction followed by 
ethanol precipitation after each round of treatment. DNA was then subject to bisulfite 
conversion, sub-cloned using the TA cloning kit followed by sequencing. 
Bisulfite sequencing  
DNA was extracted from MCF7 cells using Sigma’s Genomic DNA extraction kit and 1 
μg was used for bisulfite conversion using the EpiTect Bisulfite Kit (QIAGEN), according 
to manufacturer’s instructions.  
Bioinformatics 
All datasets used in this study were either based on the hg19 genome or were converted to 
the hg19 genome using the tool liftOver (http://genome.ucsc.edu/cgi-bin/hgLiftOver). 
100 
 
 
 
Mapping peaks to annotated genome was done using Cis-regulatory Element Annotation 
System (CEAS-Package-1.0.2, http://liulab.dfci.harvard.edu/CEAS/). To mark distance 
from known transcription sites, Region-gene association graphs were generated using the 
Genomic Regions Enrichment of Annotations Tool (version 3.0.0) and the following 
parameters: Association rule: Basal+extension: 5000 bp upstream, 1000 bp downstream, 
1x106 bp max extension and curated regulatory domains included.  
To determine the relative measure of similarity between E2-dependant TDG localization 
and that of other transcription factors I downloaded all 690 datasets from the Transcription 
Factor ChIP-Seq Uniform Peaks from ENCODE/Analysis at UCSC 
(https://genome.ucsc.edu/ENCODE/downloads.html) and determined the Fisher exact test 
and the pairwise Jaccard statistic using the Bedtools (2.25.0) options “fisher” and 
“jaccard”, with default parameters, respectively.   
All motif analysis was performed using the latest version of Homer software (version 3.12) 
(http://homer.ucsd.edu/homer/).  Peak visualization was performed using IGV 
(version/site) with group normalization applied where applicable.  
Contrasting TDG localization with gene upregulation was done using GREAT software 
(using default conditions) to generate a list of genes with which TDG associates and cross-
correlating this list with expression data.   
GRO-Seq data set was overlapped with sites of TDG binding or control sites (sites which 
contained the same sized peaks but distributed randomly using the Bedtools (2.25.0) 
“shuffle” option) using Homer software (v. 3.12) following software guidelines and default 
parameters. To generate heatmaps of looping at sites of TDG binding publicly available 
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ChIA-PET data was overlapped with sites of TDG binding or control sites (sites which 
contained the same sized peaks but distributed randomly using Bedtools (2.25.0) shuffle) 
using deepTools2 (Ramírez et al., 2016). 
Gene Ontology analysis was completed using ConsensusPathDB 
(http://cpdb.molgen.mpg.de/) using default settings.  Cut-off was set at q-value > 0.05. 
Chromosome Conformation Capture (3C) 
 MCF7 cells were treated with 100 nM E2 for 45 min and were cross-linked using 1% 
formaldehyde for 10 min. The cells were then exposed to Trypsin for 5 min at 37°C 
followed by 5 min incubation with the 3C lysis buffer at 4°C. 3C was then performed as 
previously described (Hagege et al., 2007).  
Cell-to-cell adhesion 
The cell-cell adhesion assay was done as previously described (Rodriguez et al., 2008). 
Briefly, plates were rinsed twice with PBS and cells were dissociated with 3 mM EDTA. 
Cells were collected and spun at 400 RCF for 5 minutes, then resuspended in DMEM media 
and passed through a cell strainer to dissociate cell clusters. Approximately 200,000 cells 
were added in the appropriate media (DMEM) onto a 6cm petri dish. Plates were incubated 
at 37ºC on a shaking platform for 30 minutes. After this incubation period, 10 different 
fields of view were taken per dish at 10x objective. Clusters of > 4 cells were then counted 
and counts from 10 fields of view were added together for each plate. 
For cell-substrate adhesion assays MCF7 cells were grown to confluency and then treated 
with varying concentrations of Trypsin for 2 minutes, at which point images were obtained.  
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For re-adhesion assays cells were trypsinized and resuspended in full media (DMEM + 
10% FBS) and re-plated onto 6 well.  Images were obtained at the times documented.   
Migration and Invasion 
For migration assays, transwell inserts with 8.0 um pores (Corning, Cat. No. 3422) were 
coated with 3 µg of gelatin and allowed to dry overnight at room temperature in a sterile 
environment. The following morning, the gelatin-coated filters were reconstituted with 
100uL serum-free DMEM for 90 minutes on a shaker. For invasion assays, transwell inserts 
with 8.0 um pores were coated with 100 µL of 1mg/mL Matrigel (Corning, Cat. No. 
356234) and incubated at 37ºC for one hour to allow for solidification of the Matrigel layer. 
For both assays, MCF7 cells transiently transfected with siC or siTDG RNA for 3 days 
prior to being treated with or without tamoxifen.  3 days after treatment, cells were 
harvested using 3mM EDTA. A cell suspension of 100,000 cells in DMEM + 0.1% BSA 
was added to the upper well of each transwell insert, and 750uL of DMEM + 10% FBS 
was added to the lower chamber as a chemoattractant. The cells were incubated at 37ºC 
and allowed to migrate or invade for 72 h. After this incubation period, the transwell 
membranes were fixed with 1% glutaraldehyde for 20 min, followed by a 15-min stain with 
full strength hematoxylin, and brief dip in 1% ammonium hydroxide. Non-migrating and 
non-invading cells were wiped off the upper surface of the membrane with a cotton swab. 
Images of 3 non-overlapping fields of view per well were acquired using Image-Pro 
Analysis Software on an inverted microscope at 10X objective. Cells were counted using 
ImageJ. Means derived from four replicates were used during analysis. 
Primers used in study listed in Table 2-1. 
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File Sources listed in Table 2-2. 
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Table 2-1. Primers used in study. 
ChIP Primers  
TFF1_eChIP_F GTTTGTGACCCAGGCATCTT 
TFF1_eChIP_R CAGGGTCCTGTCATTGTGTG 
GREB1_ChIP_F GCTAACCATGCTGCAAATGA 
GREB1_ChIP_R ACACAGTCAGGGCAAAGGAC 
SIAH2e_F ATCCAATTGCTGCAGGTCAC 
SIAH2e_R TCCAGGCAAGGTCACTAAGG 
TSKUe_F TCAGAACGCTCGACCTAGTC 
TSKUe_R TCAGGGCAGGACACATGATT 
Neg. Control_F CATGATTCTCGGGATTTTTCTC  
Neg. Control_R GACAGCTCTGCACCTGTCAT    
3C Primers  
GREB1_3C_Bait GGGTGCTTAGCATGGTACCTGGCAC 
GREB1_3C_Enhancer GATCATACAGTCCCGTCTTCCCTTCCTTCA   
Enhancer RNA Primers  
TFF1e_F1 GTTTGTGACCCAGGCATCTT 
TFF1e_R1 CAGGGTCCTGTCATTGTGTG 
TFF1e_F2 AGGGGATGTGTGTGAGAAGG 
TFF1e_R2 GCTTCGAGACAGTGGGAGTC 
GREN1eRNA_F1 GCTAACCATGCTGCAAATGA 
GREB1eRNA-R1 ACACAGTCAGGGCAAAGGAC 
GREB1eRNA_F2 TTGATCTGCTCTTGCCTGAA 
GREB1eRNA-R2 GTCCTTTGCCCTGACTGTGT 
SIAH2e_F ATCCAATTGCTGCAGGTCAC 
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SIAH2e_R TCCAGGCAAGGTCACTAAGG 
TSKUe_F TCAGAACGCTCGACCTAGTC 
TSKUe_R TCAGGGCAGGACACATGATT   
Bisulfite sequencing Primers  
TFF1_enhancer_bis_REV GAATTGGAGGGGAGTAGTATGAG 
TFF1_enhancer_bis_FOR GACACACCAAAAAACATCCC  
GREB1_enchancer_bis_FOR GGTTTTAAGAGGATTATAAAGAGTG 
GREB1_enchancer_bis_REV CCCACACTTCCAAAATAACAC     
Taq-man probes Catalogue Number 
GAPDH Hs02758991_g1 
GREB1 Hs00536409_m1 
TFF1 Hs00170216_m1 
HSPB8 Hs00205056_m1 
SIAH2 Hs00192581_m1 
TSKU Hs00539298_s1 
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Table 2-2. External file sources used in study. 
Assay Target Treatment ENCODE GEO 
MCF7 gene 
expression 
N/A -/+E2 N/A GSE36683 
MCF-7 Global 
Bisulfite 
sequencing 
N/A N/A N/A GSE54693 
Gro-seq N/A -/+E2 N/A GSE45822 
ChIA-PET POLR2A N/A ENCSR000CAA N/A 
ChIA-PET CTCF N/A ENCSR000CAD N/A 
ChIA-PET ESR1 N/A ENCSR000BZZ N/A 
ChIA-PET POLR2A N/A ENCSR000CAA N/A 
ChIP-seq H3K4me2 N/A ENCSR875KOJ N/A 
ChIP-seq H3K4me3 N/A ENCSR000DWJ N/A 
ChIP-seq H3K9me3 N/A ENCSR000EWQ N/A 
ChIP-seq H3K27me3 N/A ENCSR000EWP N/A 
ChIP-seq H3K27Ac N/A ENCSR000EWR N/A 
ChIP-seq GATA3 N/A ENCSR000EWV N/A 
ChIP-seq TCF7L2 N/A ENCSR000EWT N/A 
ChIP-seq ZNF217 N/A ENCSR000EWU N/A 
ChIP-seq EP300 N/A ENCSR000BTR GSM1010800 
ChIP-seq HA_E2F1 N/A ENCSR000EWX GSM935477 
ChIA-PET ESR1 N/A ENCSR000BZZ GSM970212 
DNAse-Seq N/A N/A ENCSR000EPJ GSM736588 
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Chapter 3. Role of Thymine DNA Glycosylase in 
Senescence. 
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3.1 Introduction 
Senescence describes a state of persistent cell-cycle arrest that was originally observed in 
mammalian cells after excessive passaging (Hayflick and Moorhead, 1961).  The cause of 
senescence was originally attributed to excessive telomere depletion that occurs as a 
consequence of the ‘end replication problem’.  Once cells have reached their proliferative 
potential, telomere depletion results in a complex DNA damage response that ultimately 
leads to the upregulation of several cell-cycle inhibitors and depletion of pro-mitotic 
signals, resulting in observed cell-cycle arrest (d’Adda di Fagagna et al., 2003). In addition 
to prolonged passaging, a wide range of stressors such as hydrogen peroxide treatment 
(Guo et al., 2010), oncogene activation (Benanti and Galloway, 2004), and exposure to 
U.V. radiation (Mirzayans et al., 2008) induce senescence in a telomere independent 
manner. Furthermore, senescence has been observed to play critical roles in many 
fundamental processes including tissue remodeling, wound healing, aging, and most 
recently, embryonic development (Muñoz-Espín et al., 2013; Storer et al., 2013; Zhang et 
al., 2014). Senescent cells differ from their normal counterparts in numerous ways 
including having an enlarged cytoplasm, being able  to cleave X-gal under acidic 
conditions, and expressing a unique protein profile that includes various tumor suppressors 
(i.e. p53, p21,ARF) including CKDN2A (Salama et al., 2014).  Most cells with an activated 
senescence program, while non-proliferative, remain metabolically active and exhibit a 
“Senescence Associated Secretory Phenotype” (SASP), secreting cytokines, chemokines, 
metalloproteases and growth factors (Pérez-Mancera et al., 2014; Storer et al., 2013). This 
secretion profile results in inflammation and recruitment of immune cells which then act 
to clear the senescent and/or damaged cells. Senescence of cells followed by immune 
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system engagement and clearance is believed to underpin the beneficial effects of 
senescence in tumor suppression, tissue remodeling and embryonic development. In 
contrast, the accumulation of senesced cells, or the inability to clear them, has been 
implicated in the progression of disease, increased tumor aggressiveness, accelerated 
aging, and other pathologies (Lujambio, 2016).   
Although cells undergoing senescence share certain common markers, it has become 
increasingly clear that the molecular mechanisms that regulate and establish senescence 
can vary depending on cell-type or context (i.e. what stressor led to the senescence). While 
therapeutic approaches, both pro- and anti-senescence have been considered, a deeper 
understanding of the processes that underlie senescence is required to determine under 
what contexts their use is warranted or appropriate.   
A chromosomal region highly implicated in early senescence is the INK4 locus which 
encodes the cell cycle inhibitors CDKN2A, CDKN2B, and p14ARF. p14ARF inhibits 
mdm2 which is a negative transcriptional regulator of p53.  This causes an increase in the 
concentration of p53 and induces cell-cycle arrest through the p53 pathway (Williams et 
al., 2014). CDKN2B and CDKN2A both act by inhibiting CDK4/6, which in turn prevents 
phosphorylation of Rb, allowing it to remain bound to E2F1, thereby preventing activation 
of genes required for G1/S transition (Williams et al., 2014). Importantly, CDKN2A has 
been shown to be critical in the maintenance of senescence and preventing cells from re-
entering the cell-cycle (Rayess et al., 2012). The importance of this locus continues to be 
highlighted by numerous studies showing that the absence of these tumor suppressors, 
often due to epigenetic silencing or deletion, is tightly correlated with the onset and 
progression of various cancers corresponding with the loss of senescence and, often times, 
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poor prognosis (Beauséjour et al., 2003; Bihl et al., 2012; Lou-Qian et al., 2013; Shim et 
al., 2000; Wang et al., 2012) . Furthermore, epigenetic silencing of CDKN2A involving 
promoter methylation, has been implicated as a mechanism through which cancer cells can 
overcome the senescence program (Monasor et al., 2013). In certain contexts, 
demethylation of the  CDKN2A promoter has been shown to lead to its re-expression 
resulting in cellular senescence (Vogt et al., 1998). Understanding how transcription of 
these products is regulated is critical to developing our understanding of how cancer 
overcomes inherent barriers to proliferation and will help us to identify potential 
therapeutic targets. 
Thymine-DNA Glycosylase (TDG), a member of the monofunctional glycosylase family, 
plays an important role in activating the INK4 protein CDKN2B (Thillainadesan et al., 
2012).  TDG  is a base excision repair enzyme capable of catalyzing the removal of certain 
mispaired nucleotides (Cortázar et al., 2007). Upon cleaving its substrate, TDG leaves an 
abasic site that is subsequently repaired by the BER program(Sjolund et al., 2013). 
Interestingly, TDG associates with other coregulators, such as the Creb binding protein and 
p300 (CBP/p300)(Tini et al., 2002) as well as steroid receptor coactivators (SRCs)(Hu et 
al., 2010) and can function as a coactivator by interacting with various transcription factors, 
such as nuclear hormone receptors (Chen et al., 2003; Um et al., 1998).  
The generation of  TDG homozygous knockout mice  revealed that the loss of TDG results 
in embryonic lethality at day E11.5 (Cortázar et al., 2011; Cortellino et al., 2011). 
Importantly, aberrant promoter hypermethylation, concomitant with the emergence of 
repressive histone marks and loss of activating marks at many genes was observed. 
Furthermore, the targeting of coregulators and other proteins known to interact with TDG, 
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such as CBP/p300 was also disrupted. Surprisingly, increases in random DNA mutation 
due to loss of TDG was not observed (Wu and Zhang, 2014) suggesting that the loss of 
epigenetic reprogramming during development is likely responsible for the lethality. 
Complementary studies examining the effects of TDG loss in mouse embryonic stem cells 
(mESCs) showed an accumulation of TDG substrates (5fC and 5caC) known to be 
generated through the proposed active demethylation pathway, confirming that loss of 
TDG impacts active demethylation in development (Raiber et al., 2012; Shen et al., 2013; 
Song et al., 2013). 
Recent studies have shown that mouse embryo’s initiate a robust senescence program 
during development that is maintained from E10.5 to E18.5. During this time, distinct 
patterns of strongly senescing cell can be observed at various structures including the otic 
vesicle, fusing neural tube and lining of the limbs.  Importantly, mice deficient in genes 
critical to the initiation and/or maintenance of senescence exhibit defects in senescence 
patterning and developmental abnormalities at these structures (Muñoz-Espín et al., 2013; 
Storer et al., 2013; Zhang et al., 2014).  
In this study, I explored the role that TDG plays in senescence in two distinct systems: fully 
differentiated lung fibroblasts as well as in embryonic development.  I find that exposing 
the human lung fibroblast cell-line, IMR-90, to oxidative stress in the form of sublethal 
doses of H2O2, initiates senescence as was evident through cell-cycle arrest, CDKN2A 
production, and positive β-galactosidase staining.  siRNA-mediated Depletion of TDG 
using siRNA diminishes the H2O2-mediated cell-cycle arrest and positive β-galactosidase 
staining.  Importantly, I show that TDG depletion prevents CDKN2A upregulation in 
response to H2O2 and cells depleted of TDG have lower levels of CDKN2A than their wild-
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type counterparts.  Mechanistically, I show that TDG can bind to the CDKN2A promoter 
and this binding is significantly increased when cells are expose to H2O2.  Importantly, I 
find that TDG is required for the recruitment of CBP/p300, a histone acetyltransferase that 
plays critical roles in transcriptional upregulation.  
To explore whether TDG played any role in developmental senescence I generated a TDG-
knockout mouse model and stained embryos for β-galactosidase.  Remarkably, I find that 
TDG-KO and TDG-HET mice exhibit perturbed senescence patterning at specific 
structures during development. RNA-Seq on whole mount embryos revealed that 
transcription differences between TDG-KO and WT mice are not global and instead occur 
at a specific set of genes.  However, I show that TDG’s role in developmental senescence 
occurs independent of its role in regulating CDKN2A and using gene-enrichment analysis 
find that TDG deletion causes a downregulation of genes which are important to 
establishing senescence and specifically SASP.  Taken together our findings suggest that 
TDG is a key regulator of senescence and may impact senescence in other contexts. 
 
3.2 Results 
3.2.1 TDG is required for developmental and H2O2-induced 
senescence. 
Sublethal doses of H2O2 have been previously show to induce senescence in IMR90 human 
lung fibroblast cells, causing them to cease proliferation and stall in the G1 phase of the 
cell cycle, with cells exhibit the typical markers of senescence (Chen et al., 1998a).  To 
establish whether TDG plays a functional role in initiation or maintenance of the 
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senescence program in fibroblasts I first depleted TDG from IMR-90 cells using siRNA 
targeting TDG and then treated cells with senescence-inducing concentrations of H2O2 and 
monitored their proliferation. In response to H2O2 IMR90s show substantial reduction in 
proliferation capacity and depletion of TDG increased proliferation compared to controls 
(Figure 3-1A).  In addition to reduced proliferation, a widely used marker for senescence 
is β-galactosidase activity at an acidic pH. In wild-type cells, β-galactosidase is not active 
at a pH of 6.0, however cells with an active senescence program exhibit a drastically 
increased lysosomal mass and increased levels of lysosomal β-galactosidase allowing it to 
cleave its substrate under acidic conditions (Dimri et al., 1995; Kurz et al., 2000). To test 
whether the decrease in proliferation response upon TDG depletion is indeed due to a 
defective senescence program I again exposed IMR90s to sublethal levels of H2O2 post 
TDG depletion and measured the ability to cleave 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-gal), a β-galactosidase substrate (Dimri et al., 1995).  While the 
population of IMR90s already contains a small subpopulation of senescent cells prior to 
treatment, H2O2 causes the number of senescent cells increases approximately 5-fold. 
Importantly, consistent with the proliferation assay results, TDG depleted IMR90s show 
significantly less staining than the controls (Figure 3-1B).  I repeated this experiment in 
another fibroblast cell line (HFL-1 cells) and found a similar dependency on TDG to 
initiate senescence program, suggesting that the results in IMR90s may extend to other 
adult tissue as well (Figure 3-1C).   
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Figure 3-1. TDG is required for proper senescence response in fibroblasts. 
 (A) IMR90’s were treated with either control or H2O2, and either siRNA targeting TDG 
or a scrambled non-targeting siRNA.  Left panel – Western Blot.  Right panel – Growth 
curve (Cells were counted every 24 h (n=3)) (B) Left panel - IMR90 cells were treated with 
siRNA for 3 d then treated with H2O2 for 5 d at which point they were stained for the 
senescence marker β-galactosidase using X-gal.  Right panel - Manual quantification of 
staining for IMR-90s. (C) Staining of HFL-1 cells. 
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Recent work has revealed that senescence plays an important role in developing mouse 
embryos(Ewald et al., 2010; Muñoz-Espín et al., 2013; Storer et al., 2013; Zhang et al., 
2014). TDG knockout mouse models have previously shown that homozygous deletion of 
TDG is embryonic lethal, however the role of senescence in these models was not 
established. To determine whether TDG is important for the establishment of correct 
developmental senescence patterning, our lab developed mice containing a homozygous 
and heterozygous deletion of TDG-KO and TDG-HET, respectively (Figure 3-2 A-C).  
Mice heterozygous for TDG were bred and at E10.5 pups were sacrificed and stained for 
β-galactosidase activity.  Using a double-blind study, I found that wild-type mice display 
senescence patterning consistent with previous reports showing specific staining of various 
structures including the ridges of front and hind limbs as well as the otic vesicles.  
Remarkably, mice depleted of TDG show severe disruptions in a dose dependent manner, 
with homozygous TDG-KO mice showing more severe disruption, based on staining, than 
the TDG-HET mice (Figure 3-2D and 2E).   
 
3.2.2 TDG mediates senescence in IMR90s by regulating 
CDKN2A transcription. 
In addition to G1-phase arrest and β-galactosidase staining at pH 6.0, CDKN2A is an 
established marker that is upregulated in senescent cells (Figure 3-3A). To establish 
whether TDG regulates transcription of CDKN2A, I treated IMR90 cells with a sub-lethal 
concentration of H2O2, following siRNA mediated TDG depletion, and immunoblotted for 
CDKN2A. I observed that CDKN2A expression is increased in  
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Figure 3-2. TDG is required for senescence response during development. 
(A) Schematic diagram of the strategy used to create the TDG-knockout mouse using the 
flox-CRE system (B) Western blot of whole cell lysate of tissue obtained from TDG-WT 
and TDG-KO embryos. (C) RNA-Seq analysis of the TDG locus in mice.  The TDG 
transcript was disrupted by removing exon 2. (D) β-Galactosidase staining of mouse 
embryos revealed a defect in senescence in TDG-KO and HET mice in the chest cavity 
(red perimeter), at the otic vesicle (white arrows) and apical ectodermal ridge. (H) Staining 
at the otic vesicles, as well as both front and back limb buds on both sides of the body was 
recorded and shown as a percentage of total (n = 10, N/A = indeterminate due to absence 
of structure or inconclusive staining). 
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response to H2O2, and depletion of TDG prevents the H2O2-mediated increase (Figure 3-
3B and 3C). IMR90s are typically believed to be a “late passage” cell line and possess 
“high” basal levels of CDKN2A, consistent with our observations (Benanti and Galloway, 
2004). Surprisingly however, TDG depletion not only prevented the H2O2-mediated 
increase in CDKN2A protein levels but cells treated with siTDG exhibited lower levels 
than our wild-type controls. To explore this further, I titrated the amount of siTDG 
transfected and observed that CDKN2A levels progressively decrease in response to 
increased TDG depletion (Figure 3-3D), confirming that CDKN2A expression is 
dependent on endogenous TDG levels in IMR90s 
 
3.2.3 TDG functions as a Transcriptional Coactivator in IMR90 
cells 
TDG plays a broad range of roles as a co-activator and mediates the excision of TET 
catalyzed 5mC metabolites during active demethylation. As a co-activator, TDG has been 
shown to interact and co-localize with various nuclear receptors and potentiate their 
transcriptional activity by recruiting additional co-factors (Hassan et al., 2017; Sjolund et 
al., 2013). Importantly, TDG has been previously shown, in reporter assays, to regulate 
transcription through the active demethylation of the CDKN2A locus, presumably by 
directly acting on the locus (Hu et al., 2010).  To test whether a similar mechanism governs 
H2O2 dependent transcription of CDKN2A in IMR90 cells, I first performed a ChIP using 
a TDG-specific antibody followed by qPCR using primers targeting a CpG that overlaps 
the CDKN2A promoter after treating cells with control or H2O2.  H2O2 treatment causes 
TDG localization to the CpG island overlapping the  
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Figure 3-3. TDG regulates CKDN2A expression. 
 (A) CDKN2A disrupts progression through the cell cycle by inhibiting CDK4/6. This 
prevents phosphorylation of RB. Rb in turn inhibits E2F from transcriptionally activating 
genes critical for the cell to progress into S phase. (B) Western blot of CDKN2A. CDKN2A 
response to varying levels of H2O2 was assessed in IMR90s by treating cells with H2O2 (C) 
Top panel – Western blot measuring effects of TDG depletion on H2O2 mediated CDKN2A 
induction.  IMR90 cells were treated with siRNA targeting TDG or a control for 3 d 
followed by treatment with H2O2 or control for 5 d.  Bottom panel – densitometry of 
western blot.  (D) Top panel - Western blot showing effect of increased concentration of 
siRNA targeting TDG on endogenous CDKN2a levels in IMR90s.  Bottom panel - 
Quantitation of western blot using densitometry.  
  
141 
 
 
 
 
 
 
  
142 
 
 
 
CDKN2A promoter (Figure 3-4A-C).  To determine whether TDG localization impacts the 
methylation status of the CDKN2A promoter, I performed bisulfite sequencing on a region 
of the same CpG island to which TDG localizes.  Consistent with the high basal levels of 
CDKN2A observed in IMR90 cells, bisulfite sequencing revealed that CpGs in the region 
are hypomethylated and treatment with H2O2 or TDG depletion did not significantly 
change the methylation status (Figure 3-4D).  These findings suggested that TDG 
regulation of CDKN2A levels in response to H2O2 is independent of its role in active 
demethylation.  
CBP and p300 are coactivators and lysine acetyltransferases that share a large sequence 
homology with one another and therefore contain the same set of functional domains and 
interacting partners.  While recent reports have observed differences in the specificity when 
certain factors (i.e. histones or acetyl-coA) are limited, functionally CBP and p300 are  
considered to be largely interchangeable, and are often referred to collectively as CBP/p300 
(Kasper et al., 2010; Roth et al., 2001).    
TDG interacts directly with CBP/p300 and has been shown to colocalize with p300 at many 
regulatory regions in ES cells (Hassan et al., 2017; Thillainadesan et al., 2012; Tini et al., 
2002; Xu et al., 2014).  To explore the possibility that TDG dependent induction of 
CDKN2A involves recruitment of CBP/p300, I treated IMR90 cells with H2O2 and 
performed ChIP-qPCR using a CBP-specific antibody. CBP is indeed recruited to the 
CDKN2A promoter in response to H2O2 and remarkably, TDG depletion using siRNA 
prevents this recruitment (Figure 3-4E and F).  Interestingly, inspection of the CpG island 
overlapping the CDKN2A promoter revealed a TCF4 binding motif near the site I 
interrogated for TDG/CBP binding.  While it remains to be seen whether TCF4 mediates  
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Figure 3-4. TDG’s role limited to that of scaffold. 
 (A) Structure of CDKN2A locus with the primers used indicated. (B) Western Blot 
showing that while siRNA mediated TDG depletion depletes TDG levels, H2O2 does not 
appear to affect TDG protein levels. (C) To assess whether or not TDG was localized to 
the CDKN2A promoter I performed a ChIP using TDG-specific antibody and found 
significant accumulation of TDG in response to H2O2 treatment (*, p<0.05). (D) Bisulfite 
sequencing of CDKN2A promoter reveals a relatively unmethylated landscape. (E and F) 
ChIP and ChIP-qPCR for CBP at CDKN2A.  IMR90 cells were treated with siRNA 
targeting TDG or control for 3 d.  Cells were treated with H2O2 for 2 h and then allowed to 
recover for 5 days before ChIP was performed (qPCR, n=3, standard error shown, p-value 
< 0.05).  
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TDG recruitment in the context of senescence, TDG is able to directly interact with TCF4 
and has been shown to be required for TCF4 mediated induction in other systems, such as 
Wnt signaling in colorectal cancer (Xu et al., 2014). Importantly, TDG interacts with CBP 
in this context, and target gene induction was concomitant with H3 acetylation of nearby 
histones (presumably due to CBP recruitment); effects which were lost when TDG was 
depleted (Xu et al., 2014).  TCF4 and CBP have also been implicated in activating 
CDKN2A transcription, however whether this was through direct binding of the CDKN2A 
promoter by TCF4 is unclear (Saegusa et al., 2006). Finally, my own work on TDG’s role 
in ER-signaling found that one of the most common binding sites overlapping that of E2-
dependent TDG binding in MCF7s, is also TCF4 – suggesting that the relationship between 
TDG and TCF-4 may span different biological contexts, perhaps even the induction of 
senescence.  Collectively, our findings point to TDG regulating CDKN2A transcription 
through its actions as a co-activator, possibly through its recruitment by TCF4, in an active-
demethylation independent manner.   
 
3.2.4 TDGs role in developmental senescence is independent of 
CDKN2A induction. 
To explore the mechanism governing TDG’s role in developmental senescence I performed 
an RNA-Seq on mouse embryos from TDG-WT and TDG-KO cohorts. Bioinformatic 
analysis revealed that statistically significant differences in expression are limited to a 
small set of genes (Table 3-1 and Figure 3-5A).  Consistent with the role of TDG as a co-
activator, I find that 89% of the genes which are differentially expressed are downregulated 
in TDG knockdown mice as compared to the WT mice (Figure 3-5B and C). In contrast to 
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our experiments in adult fibroblasts, I find that CDKN2A is not transcribed in developing 
embryos and therefore no changes in CDKN2A levels were detected between our cohorts 
(Figure 3-5D).  These findings suggest that TDG’s role in initiating or maintaining 
senescence is broader than I originally anticipated, possibly controlling senescence during 
development through different/altered pathways than in adult tissue. Senescence-
Associated Secretory Phenotype (SASP) plays a critical role in recruitment of immune cells 
in order to clear senesced cells and is believed to be critical in wound healing, tumor 
elimination, or tissue remodeling (Lujambio, 2016). More recently the pathway has been 
shown to be active during development in cells of structures undergoing senescence, 
suggesting that the clearing of senescent cells is an important aspect of tissue remodeling 
during development (Storer et al., 2013).  To determine if TDG plays a role in SASP during 
development, I performed gene-list enrichment analysis on the set of genes which are 
differentially expressed between TDG-WT and TDG-KO. I find that the top hits include, 
“Cellular response to stress”, “Oxidative Stress Induced Senescence” and “Senescence-
Associated Secretory Phenotype (SASP)” (Figure 3-5E). Pathway analysis showed 
enrichment for WNT and HEDGEHOG pathways, both of which are dysregulated during 
developmental senescence (Muñoz-Espín et al., 2013).   
To obtain a better sense of potential mechanisms governing the transcription of our gene 
list, I used the ENCODE database, which contains ChIP information detailing transcription 
factor and coactivator binding for various transcription factors under different conditions, 
to explore whether genes in our list are known to be targeted by any other factors.  
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Table 3-1. Gene list of differentially expressed genes comparing WT to TDG-KO 
mice. 
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Gene Name Fold Change (KO/WT) 
Hist1h3b -4.604730112 
Rn45s -4.28755873 
Hist1h2af -3.684236058 
Hist1h2ak -3.67188656 
Hist2h2ac -3.615758371 
Hist1h4d -2.972867629 
Hist1h3c -2.860687465 
Hist1h4a -2.823992808 
Hist1h4f -2.628734762 
Hist1h2bc -2.584279348 
Hist1h3e -2.565768432 
Hist1h4h -2.561694357 
Hist1h2bn -2.547296724 
Josd2 -2.389889399 
Hist1h4b -2.358090726 
Hist1h4c -2.355917092 
Ttr -2.351071426 
Hist1h3i -2.305073585 
Hist1h3d -2.252757216 
Hist1h2bg -2.241319199 
Hist2h4 -2.235437136 
Hist4h4 -2.209367652 
Hist1h4m -2.198653402 
Hist1h3g -2.192280045 
Rpph1 -2.178734496 
Hist1h3a -2.163438152 
Hist1h3f -2.136669521 
Rpl36 -2.034155925 
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Wnt8b -2.021315877 
C2cd2l -1.986464597 
Nckap5l -1.788602022 
Ccdc124 -1.776946992 
Hist1h2bh -1.776436736 
Hist1h1c -1.695497477 
Hist3h2a -1.66625845 
Crocc -1.638163022 
Emilin1 -1.631945943 
Ahdc1 -1.622061063 
Tmem132a -1.591152977 
Atp13a2 -1.581161763 
Ppp1r12c -1.573188929 
Csnk1g2 -1.545582514 
Hist1h2bm -1.538673476 
Scaf1 -1.536761083 
Rmrp -1.518211721 
Megf6 -1.511055323 
Hist1h1d -1.510416071 
Pold1 -1.505032589 
Rplp2 -1.489131856 
Pcnxl3 -1.483877776 
Ints1 -1.478801309 
Rps26 -1.476415794 
Ckb -1.47591883 
Col2a1 -1.452279539 
Gnb2 -1.443453794 
Myh7 1.660958515 
Actc1 1.826025366 
Ttn 1.8467956 
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Myom1 1.953907359 
Myl1 2.075705638 
Nppa 3.236279189 
Myl2 3.328548459 
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Figure 3-5. Transcription profiles of TDG deficient mice compared to WT. 
 (A)  PCA analysis comparing WT and KO mice found that the global transcription profiles 
were similar between cohorts and, instead, what I found was that TDG deletion caused a 
significant change in a small subset of genes.  (B) Changes in gene-expression between 
TDG-KO and TDG-WT mice revealed that most genes underwent down regulation in 
TDG-KO mice as compared to TDG-WT, consistent with previous reports finding that 
TDG acts primarily as a co-activator, c. (C) Heatmap looking at gene-expression profiles 
in WT and KO mice. (D) Transcript levels of CDKN2A and various house-keeping genes 
in both TDG-KO and WT mice.  (E) To determine what pathways were affected by TDG 
knockdown gene enrichment analysis was performed using the Reactome database (Subset 
of significant results shown).    
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Remarkably, I find that the highest enrichment came from p300 and SP1: ChIP analysis 
revealed that 32 (48%) of the genes in our list have been shown to recruit p300, while 39 
(59%) have shown to recruit SP1 (Table 3-2).  This data suggests that the mechanism 
governing expression of these genes may be similar to the mechanism governing H2O2-
mediated expression of CDKN2A in IMR90, however further work is required to test this 
proposition.  Collectively these suggest that TDG is required for developmental 
senescence, and that its role is independent of CDKN2A regulation. 
 
3.3 Discussion 
Senescence, originally shown to be a cellular program that limits proliferative potential, 
has more recently been shown to be a critical component of various fundamental processes, 
modulating cellular response to oncogenic stress and reactive oxygen species, wound 
healing, tissue remodeling and, most recently, embryonic development.  While a proper 
senescence program is able to promote positive outcomes, errors in senescence have been 
shown to be detrimental to health. Building a comprehensive understanding of how 
senescence is initiated and maintained is a critical step toward developing therapies that 
can appropriately modulate senescence in a therapeutic context. 
In this study I find that TDG, a base-excision protein with an expanding list of roles, is a 
critical mediator of distinct forms of senescence.  In a model of senescence in the IMR90 
human lung fibroblast cell, I demonstrated that depletion of TDG leads to an attenuated 
response to H2O2: effects of H2O2 on proliferation and β-galactosidase staining are 
attenuated and CDKN2A induction abrogated. Furthermore, in response to H2O2, I show  
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Table 3-2. ENCODE transcription factor binding at genes whose transcription was 
significantly altered in WT vs TDG-KO mice. 
The list of gene that were identified as being significantly downregulated upon TDG 
knockout in our RNA-Seq data were compared to the ENCODE (2014) database using 
Enrichr software.  Bolded are instances of SP1 and p300. 
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Term Adjusted P-value Genes 
P300_SK-N-
SH 
0.000187686 
HIST1H2BN;CCDC124;HIST2H2AC;HIST1H3A;NPPA;RPL36;RPLP2;EMILIN1;HIST1H3I;CKB;
HIST1H3B;HIST1H3E;INTS1;HIST1H2AK;NCKAP5L;TMEM132A;JOSD2;SCAF1;RPS26;HIST1
H4A;HIST1H4B;HIST4H4;GNB2;HIST1H4H;HIST1H2BH;HIST1H2BG;HIST1H4C;HIST1H4D;
PPP1R12C;AHDC1;HIST1H4F;HIST1H2BC 
SP1_H1 0.000187686 
HIST1H2BN;HIST1H2BM;CCDC124;HIST2H2AC;RPPH1;HIST1H3A;POLD1;HIST1H3F;RPL3
6;HIST1H3G;RPLP2;HIST1H3I;HIST1H3B;HIST1H3D;RMRP;HIST1H3E;NCKAP5L;HIST1H2A
K;JOSD2;SCAF1;RPS26;HIST1H4A;HIST3H2A;HIST1H4B;COL2A1;HIST4H4;GNB2;CROCC;H
IST1H2BH;ATP13A2;HIST1H2BG;HIST1H4C;PCNXL3;HIST1H4D;PPP1R12C;CSNK1G2;C2CD
2L;HIST1H2BC;HIST1H4F 
IRF3_HELA-
S3 
0.000419177 
HIST1H2BN;HIST1H2BM;HIST1H2AK;HIST2H2AC;HIST1H4A;HIST1H3A;HIST3H2A;HIST1H
3F;HIST1H3G;HIST1H2BH;HIST1H2BG;HIST1H4C;HIST1H3B;PCNXL3;HIST1H3C;HIST1H3D
;HIST1H2BC;HIST1H1C 
MEF2A_K56
2 
0.000984914 
HIST1H2BN;HIST1H2AK;CKB;HIST1H4D;C2CD2L;HIST1H3D;HIST1H2BC;HIST2H2AC 
P300_H1 0.001381286 
INTS1;TMEM132A;CCDC124;JOSD2;SCAF1;HIST2H2AC;HIST1H4A;HIST1H4B;HIST4H4;GN
B2;HIST1H4H;RPLP2;HIST1H3I;CKB;HIST1H4C;HIST1H3B;PCNXL3;HIST1H4D;PPP1R12C;C
SNK1G2;HIST1H4F;HIST1H3E 
RXRA_GM12
878 
0.001381286 
HIST1H2BM;INTS1;CCDC124;JOSD2;SCAF1;HIST2H2AC;HIST1H4B;HIST4H4;GNB2;HIST1H
3F;HIST1H4H;HIST1H2BH;HIST1H4C;HIST1H4D 
NF-YB_K562 0.001381286 
HIST1H2BN;HIST1H2BM;HIST2H2AC;HIST1H3A;HIST1H1D;HIST1H3F;RPLP2;HIST1H3G;C
KB;HIST1H3I;HIST1H3B;HIST1H3C;HIST1H3D;HIST1H1C;HIST1H2AK;NCKAP5L;JOSD2;RPS
26;HIST1H4A;HIST3H2A;GNB2;HIST1H2BH;HIST1H2BG;PCNXL3;HIST1H2BC 
GTF2B_K562 0.001718723 
HIST1H2BN;HIST2H2AC;RPPH1;HIST1H3A;HIST1H1D;RPL36;RPLP2;HIST1H3B;HIST1H3D;
HIST1H1C;RMRP;INTS1;HIST1H2AK;NCKAP5L;SCAF1;RPS26;HIST1H4A;HIST3H2A;GNB2;
HIST1H4H;HIST1H2BH;HIST1H2BG;HIST1H4D;PPP1R12C;C2CD2L;AHDC1;HIST1H2BC 
FOS_GM128
78 
0.001922636 
HIST1H2BN;HIST1H2BM;HIST1H2AK;HIST3H2A;HIST1H3A;HIST1H3G;HIST1H3I;HIST1H2
BG;HIST1H3B;PCNXL3;HIST1H3C;HIST1H3D;HIST1H2BC 
IRF3_GM128
78 
0.00274444 
HIST1H2BN;HIST1H2BM;HIST1H2AK;HIST2H2AC;HIST1H4A;HIST1H3A;HIST3H2A;GNB2;
HIST1H3F;HIST1H3G;RPLP2;HIST1H2BH;HIST1H3I;HIST1H2BG;HIST1H4C;HIST1H3B;PCN
XL3;HIST1H3C;HIST1H3D;CSNK1G2;HIST1H3E;HIST1H2BC 
NRSF_H1 0.00274444 
HIST1H2BN;HIST1H2BM;HIST1H3A;HIST4H4;HIST1H2AK;HIST1H4H;HIST1H4C;HIST1H4D
;HIST1H4F;RMRP;HIST2H2AC;HIST1H2BC 
JUND_HELA-
S3 
0.00274444 
HIST1H2BN;HIST1H2BM;HIST1H4A;RPPH1;HIST1H2AK;HIST1H4H;HIST1H2BG;HIST1H4C;
SCAF1 
NFE2_GM12
878 
0.00274444 
HIST1H2BN;HIST1H2BM;HIST1H2AK;CCDC124;SCAF1;HIST2H2AC;HIST1H4A;RPPH1;HIST
1H4B;HIST4H4;GNB2;HIST1H3I;HIST1H2BG;HIST1H4C;HIST1H3B;PCNXL3;HIST1H3C;HIST
1H3D;HIST1H2BC;RMRP 
NF-
YA_GM1287
8 
0.00274444 
HIST1H2BN;HIST1H2BM;HIST1H2AK;HIST2H2AC;HIST1H3A;HIST3H2A;HIST1H1D;HIST1H
3F;RPLP2;HIST1H3G;HIST1H2BH;HIST1H3I;HIST1H2BG;HIST1H3B;PCNXL3;HIST1H3C;HIS
T1H3D;HIST1H1C;HIST1H3E;HIST1H2BC 
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STAT3_HELA
-S3 
0.003883862 
HIST1H2BN;HIST1H4A;HIST3H2A;GNB2;HIST1H2AK;HIST1H2BG;HIST1H4C;PCNXL3;HIST
1H4D;HIST1H3D;HIST2H2AC;HIST1H2BC 
TCF12_SK-N-
SH 
0.003883862 
HIST1H2BN;HIST1H2AK;HIST1H4H;EMILIN1;HIST1H4C;HIST1H3B;HIST1H4D;HIST1H3D 
SRF_K562 0.004504858 
HIST1H2BN;INTS1;HIST1H2AK;CCDC124;JOSD2;SCAF1;RPS26;HIST1H4A;RPPH1;GNB2;P
OLD1;HIST1H4H;RPLP2;ATP13A2;PPP1R12C;CSNK1G2 
CJUN_HEPG
2 
0.005594011 
HIST1H2BN;HIST1H2BM;RPPH1;HIST4H4;HIST1H2AK;CCDC124;HIST1H4H;RPLP2;HIST1H
2BG;HIST1H4C;HIST1H3B;SCAF1 
CEBPB_GM1
2878 
0.008449704 
HIST1H2BN;HIST1H2BM;HIST1H2AK;CCDC124;HIST2H2AC;RPS26;HIST1H4B;HIST3H2A;H
IST4H4;GNB2;HIST1H4H;RPLP2;HIST1H3I;HIST1H2BG;HIST1H3B;PCNXL3;HIST1H4D;HIST
1H3D;HIST1H3E;HIST1H2BC 
NF-YA_K562 0.009152463 
HIST1H2BN;HIST1H2AK;HIST2H2AC;HIST1H4A;HIST1H3A;HIST3H2A;HIST1H1D;HIST1H3F
;RPLP2;HIST1H2BH;CKB;HIST1H2BG;HIST1H4C;HIST1H3B;PCNXL3;HIST1H3D;HIST1H1C;
HIST1H2BC 
BRF2_HELA-
S3 
0.009152463 
RPPH1;RMRP 
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that TDG localizes to a CpG island overlapping with the promoter of CDKN2A and recruits 
the co-activator CBP, leading to CDKN2A’s transcription.  Importantly, no change in the 
methylation status of the CDKN2A promoter was found in TDG depleted IMR90 cells.  
Recent work in ESCs found that TDG depletion led to the accumulation of the active 
demethylation metabolites 5caC and 5fC.  Bisulfite sequencing is unable to identify these 
metabolites, which would register the same readout as unmodified cytosines.  It is therefore 
possible that changes in the metabolite landscape is altered at this site, however further 
studies will be needed to investigate this possibility.  
While senescence has traditionally been shown to be a response to different forms of 
cellular stress, recent work has revealed that the senescence program plays critical roles 
during embryonic development in mice (Muñoz-Espín et al., 2013; Storer et al., 2013; 
Zhang et al., 2014). To test whether TDG is important during embryonic senescence, I 
generated a TDG-HET and TDG-KO mouse and assayed for the senescence marker β-
galactosidase during embryonic development. Mice which have depleted TDG show 
perturbed staining at structures that undergo senescence. CDKN2A is not expressed during 
embryonic development and therefore does not play a role in the establishment of 
senescence as it does in adult fibroblasts. This finding is consistent with reports 
highlighting that many of the key players in the senescence of differentiated tissue are 
likely not drivers of the developmental senescence program (Campisi and D’Adda Di 
Fagagna, 2007; Collado et al., 2007). Indeed, investigation into the ectodermal ridge, a 
structure which undergoes senescence at approximately E10.5 revealed that while a subset 
of known senescence markers were expressed, important markers like p53, p19, or 
CDKN2A were not expressed (Storer et al., 2013). Gene-enrichment analysis on the set of 
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genes that are differentially regulated between TDG-WT and TDG-KO revealed a 
significant enrichment for the categories, “Oxidative Stress Induced Senescence” and 
“Senescence Associated Secretory Phenotype”.  Closer inspection of the genes which 
underlie these subsets finds that the major statistically significant positive hits are due to a 
differential expression of histones between the two cohorts.  More specifically, histone 
transcription of various histones appears to be downregulated in TDG knockout in mice: 
of the 66 genes which are downregulated in our TDG knockout mice, 29 (44%) are histones 
(Table 3-1). Limited information is available regarding histone dynamics during 
senescence.  Certain levels of certain histone variants like linker histone H1 have been 
shown to decrease during certain forms of senescence, while other variants appear to 
decrease (Contrepois et al., 2017; Funayama et al., 2006).  Levels of histone marks also 
change, but the directionality of the changes is believed to dependent on the ‘type’ of 
senescence program initiated (Parry and Narita, 2016).  Determining whether histone 
dysregulation is important for embryonic senescence will require additional studies in order 
to fully understand the significance of these observations.  
Observing differences in the expression of senescence-associated terms and proteins, even 
though our RNA-Seq was performed on the entire embryo rather than limited to the cells 
which undergo differential senescence, suggests that TDG may ‘prime’ cells for 
senescence en masse, which allows for cell-type specific factors to drive senescence in 
certain structures and not others.  Further work, including RNA-Seq targeted at 
differentially senesced structures in TDG-WT and TDG-KO mice is necessary to determine 
whether this is indeed the case. 
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Taken together our findings are the first to show that TDG is general mediator of 
senescence and, importantly, is able to drive senescence through distinct pathways. Indeed, 
TDG is one of the few molecules which appear to drive senescence programs in both 
development and adult tissue. While manipulation of the senescence program is being 
explored as a therapeutic strategy to overcome various pathologies, major hurdles remain.  
One of the biggest issues is that the effects of senescence appear to have both beneficial 
and/or detrimental effects depending on context. For example, the initiation of senescence 
in tumors leads to SASP which recruits the immune system, resulting in tumor regression 
and preventing tumor re-growth.  Paradoxically, in other cases the initiation of senescence 
and SASP, has also been shown to be tumorigenic, increasing the aggressiveness and rate 
at which tumors progressed.  Whether this is due to a defect in the senescence program, the 
immune system, or something else entirely, is not clear.  To resolve these sorts of questions 
and identify new therapeutic targets, identifying important factors and the context under 
which they function will be required. 
 
3.4 Materials and Methods 
Cells culture, treatment and transfections 
IMR-90 and HFL cells were obtained from ATCC and grown in DMEM supplemented 
with 10% Fetal Bovine Serum (FBS). Cell were washed with DMEM and treated with 
H2O2 for 2 h at which point they were washed twice and then replaced with DMEM. Stock 
H2O2 (30%) was diluted with media to obtain desired concentration/amount prior to 
treatment.  siRNA treatments were performed using Lipofectamine 2000 
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(LifeTechnologies) according to the manufacturer’s instructions.  Cells were treated for 
siRNA targeting TDG (Dharmacon, M-040666-01) or scrambled siRNA (Dharmacon, D-
001210-03) for 24h at which point cells were washed once and media was replaced with 
fresh DMEM.  
Protein extraction and Immunoblotting 
Whole cell protein extracts were obtained by harvesting cells in RIPA lysis buffer (50mM 
Tris (pH 8) 0.15M NaCl, 1% NP40, 0.5% sodium cholate and 0.1% SDS).  Cells were 
incubated on ice for 15min and centrifuged for 15 min at 4°C (~20,000 RCF). Protein 
concentrations were normalized, and proteins were separated by SDS-PAGE then 
transferred to PVDF for 1 hr. The PVDF membrane was placed in blocking buffer 
consisting of PBS, 0.1% Tween-20 and 5% skim milk powder which was also used for 
primary and secondary incubation as well as washes. All secondary antibodies used are 
conjugated to horseradish peroxidase (HRP). To visualize proteins, chemiluminescence 
film (Anersgan Hyperfilm ECL) was exposed to membranes treated for 5min with 
Luminata Forte Western HRP Substrate (Cat. No. WBLUF0100). 
ChIP and analysis 
IMR90 cells were transfected with siRNA targeting TDG or control siRNA for 3 d at which 
point they were treated with H2O2 for the time specified. ChIP was performed using a 
polyclonal affinity purified TDG antibody (Thermo Fisher Cat. PA5-29140) or with a CBP 
antibody (Santa Cruz (A-22): sc-369), as previously described, with minor alterations 
(Thillainadesan et al., 2012). Briefly, cells were cross-linked using 1% formaldehyde in 
PBS for 10 min under shaking at RT. 0.125 mM glycine in PBS was then added for 5min 
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to quench the reaction. Cells were then washed twice with ice-cold PBS and harvested in 
1 ml of ice cold PBS buffer. The cells were then pelleted at 250g for 10 minutes, washed 
twice with ice-cold PBS (protease inhibitors added), and then lysed using 200 μl of lysis 
buffer (1% SDS, 50 mM Tris-HCl [pH 8.0], 10 mM EDTA, and protease inhibitors) for 15 
minutes on ice. The cell lysates were then sonicated and cell lysate was centrifuged at 
15000 rpm for 15 minutes. An aliquot of the supernatant mixture was saved as input DNA, 
and the remaining lysate was incubated with 5 ug of antibody in 50 μl of protein A/G 
dynabeads as per instructions.  ChIP was performed overnight at 4°C under rotation. The 
dynabeads were then washed twice with wash buffer I (0.1 % SDS, 1 % Triton X-100, 2 
mM EDTA, 20 mM Tris-HCl [pH 8.0], 150 mM NaCl), once with wash buffer II (0.1 % 
SDS, 1 % Triton X-100, 2 mM EDTA, 20 mM Tris-HCl [pH 8.0], 500 mM NaCl), and 
then with wash buffer III (0.25 M LiCl, 1% NP-40, 1% Na-deoxycholate, 1 mM EDTA, 
10 mM Tris-HCl [pH 8.0]) and twice with Tris-EDTA buffer (pH 8.0). The chromatin was 
eluted using 150 μl of freshly made elution buffer I (1% SDS, 0.1 M NaHCO3) twice at 
65°C for 10 minutes. NaCl was added to the eluates and to input DNA to a final 
concentration of 0.3 M and both were incubated at 65°C overnight. Immunoprecipitated 
DNA was purified using QIAquick PCR Purification Kit (Qiagen) and was analyzed by 
quantitative PCR with the indicated primers, or run on a gel, in technical triplicates and 
biological duplicates, unless otherwise noted. Primers used for promoter of CDKN2A: 
CDKN2A-ChIP-FORWARD: CTGTCCCTCAAATCCTCTGG 
CDKN2A-ChIP-REVERSE: ATTCGCTAAGTGCTCGGAGT 
Bisulfite sequencing  
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DNA was extracted from IMR90 cells using Sigma’s Genomic DNA extraction kit.  DNA 
was bisulfite-converted using EpiTect Bisulfite Kit (QIAGEN), according to 
manufacturer’s instructions.  Primers used for bisulfite sequencing:  
CDKN2A-BS-Forward: GTTGGTAAGGAAGGAGGATTGG 
CDKN2A-BS-Reverse: CTCTCCAAAAAAAATCCTTTAAAC 
 
β-galactosidase staining 
In vitro and in vivo β-galactosidase staining of IMR90 or HFL-1 cells and embryos, was 
done as previously described (Dimri et al., 1995; Keyes et al., 2005) with alterations.  
Briefly, after treatments media was removed and cells were washed twice with PBS then 
fixed with 0.2% glutaraldehyde for 5 minutes after which cells were again washed with 
PBS, and then treated with the staining mix composed of: 1mg/ml X-gal (Wisent), 150 mM 
NaCl, 2mM MgCl2, 5mM K3Fe(CN)6, 5mM K4Fe(CN)6, 40mM NaPi (Sodium phosphate 
buffer). Cells were kept at 37C for 20 hr prior to visualization.   
Mouse Protocol 
All mouse experiments were done in compliance with the Institutional Animal Care and 
Use Committee guidelines at London Regional Cancer Center at Western University and 
the University of British Columbia. To generate Tdg knockout mice, Tdg fl/fl mice were 
bred with C57BL/6 Cre-deleter mice which excise loxP flanked regions and generated the 
Tdg heterozygous constitutive knock-out mice.  These Tdg heterozygous constitutive 
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knock-out mice were bred to create the range of genotypes used for the embryonic 
senescence staining assay. 
Adult (8 weeks old) UBC-cre/ERT2; Tdgfl/fl and litter matched Tdgfl/fl controls were 
intraperitoneally injected with 3 mg TAM daily for 5 days. To assess cre-ERT2 efficiency, 
the mice were euthanized 4 weeks after TAM injections, tissues were harvested, lysed 
using RIPA buffer and western blotting performed using an anti-TDG-antibody. 
RNA-Seq and analysis 
Sample quality control was performed using the Agilent 2100 Bioanalyzer. Qualifying 
samples were then prepped following the standard protocol for the NEBnext Ultra ii 
Stranded mRNA (New England Biolabs). Sequencing was performed on the Illumina 
NextSeq 500 with Paired End 42bp × 42bp reads.  De-multiplexed read sequences were 
then aligned to the Mus Musculous (mm10) reference sequence using STAR 
(https://www.ncbi.nlm.nih.gov/pubmed/23104886) aligner. Assembly and differential 
expression was estimated using Cufflinks (http://cole-trapnell-lab.github.io/cufflinks/) 
through bioinformatics apps available on Illumina Sequence Hub. Prior to down-stream 
analysis, list of differentially expressed genes was filtered to remove genes on X and Y 
chromosomes to avoid sex bias. Pathway analysis was performed using Reactome Pathway 
Database (http://reactome.org) using default parameters. Integrative Genomics Viewer 
(IGV) was used for viewing high-throughput data-files. 
Western Blot quantification was done using ImageJ software and default parameters 
(https://imagej.nih.gov/ij/). 
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4.1 Overview 
While TDG has been previously implicated in playing a role in ERα signaling, information 
regarding the specifics of its role have been limited. To extend the role of TDG in ERα 
signaling, I performed a ChIP-Seq using an antibody targeting TDG in MCF7 cells -/+ E2, 
followed by bioinformatic analysis and conventional assays.  I found TDG was required 
for β-estradiol induction of certain ERα target genes.  Investigation into the mechanism 
through which TDG exerts its effects revealed that, in response to β-estradiol, TDG 
localizes predominantly to distal regulatory regions in ERα target genes.  Bioinformatic 
analysis revealed that these regions are bonafide enhancers and occupied by proteins 
important to enhancer function, including CBP/p300, ERα and RNA Pol II.  Using 
conventional biochemical methods in conjunction with recently developed techniques, I 
discovered that TDG is important for both the transcription of long non-coding enhancer 
RNA from targeted enhancers, as well as the 3-dimensional reorganization that brings 
together the enhancer with the associated promoter of some target genes. Depletion of TDG 
resulted in disruption of eRNA production, looping and target-gene transcription.  Taken 
together this work extends the role of TDG in ERα signaling and also uncovers a previously 
unknown role for TDG: as a regulator of eRNA transcription.  
In the context of senescence, I discovered that TDG is required for cells to mount a proper 
senescence response to oxidative stress in the form of H2O2.   Using conventional 
biochemical methods along with ChIP and bisulfite sequencing I found that TDG mediates 
its effects by upregulating CDKN2A-induction.  Importantly, TDG depletion did not result 
in changes in the methylation status of the CDKN2A promoter, suggesting that its impact 
is independent of its ability to act in the active demethylation pathway. Indeed, ChIP 
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performed using a CBP-specific antibody found that TDG is required for the recruitment 
of CBP to the CDKN2A promoter region, suggesting it is its role as a scaffold, rather than 
a mediator of active demethylation, that is responsible for activating CDKN2A expression. 
In addition to senescence in adult tissue, I sought to investigate whether TDG played a role 
in the senescence program initiated during embryonic development.  RNA-Seq on whole 
mount embryos, either wild-type or TDG-KO, revealed that TDG deletion resulted in 
defects in the developmental senescence program through a CDKN2A-independent 
mechanism. Gene enrichment analysis comparing TDG-WT to TDG-KO mice revealed 
alterations to transcript levels of genes important for “Cellular response to stress”, 
“Oxidative Stress Induced Senescence” and “Senescence-Associated Secretory Phenotype 
(SASP)” and showed that WNT and Hedgehog pathways may be impacted.  Taken together 
this work provides the first evidence that TDG plays a role in both adult and embryonic 
senescence programs. 
 
4.2 TDG’s effects as an oncogene and tumor 
suppressor.  
The question as to whether TDG is an oncogene or tumor suppressor remains elusive.  
TDG’s ability to repair mismatches and improperly modified cytosines suggests that 
knockout of TDG should result in increased mutations throughout the genome. Knockout 
studies performed in mouse model systems have found that deletion of MBD4, the 
functional homologue of TDG, resulted in increased C:T mutations, as well as increased 
tumorigenic potential when MBD4 knockout mice are bred with mice predisposed to colon 
cancer (Wong et al., 2002). Furthermore, TDG functions as a co-activator for the 
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transcriptional activation of a  variety of tumor suppressors, including CDKN2B, p21, p53, 
CDKN2A, and HIC1 (Hassan et al., 2017; Kim and Um, 2008; Thillainadesan et al., 2012). 
Collectively, this suggests that TDG may behave as a tumor suppressor and its silencing or 
mutation should be found in cancer.  However, a survey of online databases, including 
TCGA, finds that TDG mutation or silencing does not appear to be wide-spread.  Several  
interesting observations however may explain this apparent discrepancy:  Firstly, knockout 
studies of TDG found no increase in mutation load compared to wild-type mice, suggesting 
that functional redundancy compensates for any deficiencies in mutation repair imposed 
by TDG deletion (Cortázar et al., 2011; Cortellino et al., 2011).  Secondly, whatever anti-
tumor effects TDG may exert through its control of tumor suppressors or otherwise, must 
be weighed against any pro-selection advantages it may offer.  In the case of breast cancer, 
I found that depletion or knockout negatively impacts ERα signaling, which is reflected in 
the blunted response to estradiol-mediated induction of ERα target-genes and decreased 
proliferation in MCF7 cells.  ERα signaling is a key component of early breast cancer 
development and so it stands to reason that cells with a loss of TDG, which mediates ERα 
signaling, are likely selected against during tumour development.  Similar observations 
have been made in other systems as well. For example, in Wnt-driven colorectal cancer, 
the authors found that TDG was required for the upregulation of Wnt targets and drove 
cancer.  Furthermore,  no homozygous mutations for TDG are observed in CRC – 
supporting the idea that the presence of TDG is required for the establishment of the cancer 
in the first place, which ‘protects’ it from being silenced, even at the expense of tumors 
retaining the ability to repair mismatched nucleotides, or activate tumor suppressors (Xu 
et al., 2014).   
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Additionally, context appears to be a critical determinant of whether TDG acts as a tumor 
suppressor or oncogene.  For example, a conditional knockout of TDG in the intestinal and 
colonic epithelium of APCMin mice (i.e. mice predisposed to intestinal adenoma formation) 
results in significantly higher rates of tumor formation in TDG-KO mice as compared to 
the controls  (Xu et al., 2017).  Estrogen plays a protective role in colorectal cancers, with 
increased rates of tumor formation in females who have undergone an ovariectomy (Xu et 
al., 2017).  Comparing the results of ovariectomies in control mice vs TDG conditional 
knockouts, researchers found that, in contrast to the findings that TDG is a driver of 
colorectal cancer by upregulating Wnt signaling, the protective role of estrogen is likely to 
be largely TDG-dependent, supporting a role for TDG as a tumor suppressor.  Collectively 
these findings reflect similar dynamics that are observed in breast cancer where TDG 
mediates both pro- and anti-tumor effects, further highlighting its pleiotropic nature.  
 
4.3 TDG functions as a scaffold 
In my investigation into TDG’s role in ER-signaling in breast cancer as well as its role in 
senescence, I found no evidence for active demethylation when TDG is engaged.  More 
specifically, in both ERα signaling and senescence, I found that TDG localizes to 
hypomethylated regions.  In the case of senescence, I investigated the methylation status 
of the CDKN2A promoter, to determine whether depletion of TDG resulted in its 
hypermethylation and silencing of CDKN2A expression.  While TDG depletion did result 
in reduced CDKN2A levels, this was not accompanied by changes in methylation with the 
promoter remaining in a hypomethylated state.  Instead, I found TDG-dependent 
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localization of CBP to the CDKN2A promoter upon H2O2 treatment. Importantly, TDG 
depletion prior to H2O2 treatment significantly attenuates the recruitment of CBP, 
consistent with other reports that find that TDG acts as a scaffold, recruiting, among other 
important transcription factors, CBP (Chen et al., 2003; Tini et al., 2002).  While this isn’t 
always the case (TDG’s glycosylase activity has also been shown to be critical to retinoic 
acid signaling for example), it appears that TDG’s scaffolding capability is more general 
and is required in order to stabilize necessary complexes to activate transcription, while its 
glycosylase activity may only be necessary when removal of DNA methylation is required.  
In the context of ER-signaling, I found that TDG localizes to enhancers which were 
hypomethylated. Therefore, I examined the consequences of TDG knock down at two 
ER/TDG targeted enhancers (TFF1 and GREB1) using bisulfite sequencing.  Interestingly, 
I found no change in the methylation status of these enhancers, which was not entirely 
unexpected as previous reports showed that TDG knockout in mouse embryonic stem cells 
results in the accumulation of active-demethylation metabolites, rather than outright 
methylation (Raiber et al., 2012; Shen et al., 2013).  To interrogate changes to active 
demethylation metabolites during TDG depletion, I used MAB-Seq. Remarkably, I found 
that regions bound by TDG are composed almost entirely of unmodified cytosines, and this 
remained unchanged regardless of E2 treatment and/or TDG depletion.  While the lack of 
methylation at these sites explains why there is no accumulation of active demethylation 
metabolites in the absence of TDG (methylation must be present in order for active 
demethylation metabolites to accumulate), it is not clear as to what is preventing DNMT 
mediated methylation of these specific site yet allowing it to occur at other sites throughout 
the genome.    
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4.4 Future Directions 
During the course of my investigations, I discovered that TDG plays a critical role in H2O2-
induced senescence in human fibroblasts and during development. I found that TDG drives 
H2O2-induced senescence likely through the recruitment of coactivator CBP to the 
CDKN2A promoter. Importantly, while TDG appears to be important for developmental 
senescence, this occurs independent of CDKN2A, which is not expressed in either TDG-
WT or TDG-KO mice.  Whole-mount RNA-Seq comparing TDG-KO and TDG-WT mice 
identified differentially expressed genes between the two cohorts, and gene enrichment 
highlighted dysregulated pathways which may be responsible for the observed defects.  
One concern with whole mount RNA-Seq is that it may mask subtle but critical differences 
that are limited to specific structures that undergo senescence.  It will therefore be 
important to conduct an RNA-Seq on a structure (ex. the apical ecto-dermal ridge) that 
undergoes differential senescence in TDG-KO vs TDG-WT mice to formally identify 
genes which are dysregulated upon TDG knockout and which may therefore contribute to 
defects in embryonic senescence. 
While senescent cells have classically been characterized according to phenotypic traits 
and molecular markers, it has become increasingly clear that cellular senescence can take 
on many distinct forms depending on cell type as well as the stressors involved in inducing 
the senescence program.  As therapeutic approaches are being developed and tested, 
classifying different forms of senescence will be important when seeking to effectively 
target treatments.  The role of TDG in H2O2-induced senescence and in embryonic 
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senescence, appears to involve distinct pathways.  This suggests that TDG may underlie 
other forms of senescence as well.  A comprehensive survey of the literature to identify 
different forms of senescence in conjunction with siRNA mediated TDG depletion studies 
can answer whether or not this is the case.  A resource such as this would not only help 
characterize senescence (helping to establish whether certain proteins or pathways underlie 
senescence in a general sense or identify critical differences between different senescence 
programs) but would be useful for identifying new therapeutic targets.   
During my research into estrogen signaling I uncovered a novel role of TDG in gene 
transcription, finding that in response to β-estradiol, TDG mediates the transcription of 
eRNA from enhancers of ERα target genes.  Depleting cells of TDG not only inhibited the 
transcription of the eRNA’s, but also inhibited the transcription of the primary transcripts 
themselves. Furthermore, eRNA per se has been shown to mediate 3-dimensional re-
organization at ERα target genes (Li et al., 2013).  I confirmed that TDG depletion not only 
leads to a loss of eRNA production but ablates the 3-dimensional re-organization important 
for bringing into proximity the promoter, enhancer and all of the transcriptional machinery 
that resides on both regulatory regions, at the ERα target GREB1.  While I found that TDG 
regulates the production of eRNA from specific enhancers and mediates looping at one of 
these targets, it is currently unclear how prevalent this is in ERα signaling.  To obtain a 
better understanding of the importance of TDG in ERα signaling, one can use RNA-Seq 
which gives an accounting of global transcript levels, in conjunction with siRNA-mediated 
knockdown studies. Alternatively, global run-on sequencing (GRO-Seq) can be used which 
accurately depicts nascent transcription, to determine the global role of TDG in both eRNA 
transcription as well as mRNA transcription.  In conjunction with insight into how TDG 
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alters transcription of eRNA and mRNA, tools and technologies such as chromatin 
conformation capture sequencing (Hi-C) would allow us to determine 3-dimensional 
chromosome organization and how TDG impacts changes. Integrating this new data with 
our ChIP-Seq, would provide a detailed overview the role of TDG in ERα signaling.  
Interestingly, in many studies approximately the same number of genes are repressed upon 
E2 treatment as are activated (Osmanbeyoglu et al., 2013).  The mechanism through which 
repression occurs is not clear. However recent work has revealed 3-dimensional 
reorganization may govern E2-mediated repression (Osmanbeyoglu et al., 2013).  
Importantly, E2 treatment in MCF7 cells disrupts the 3-dimensional organization at a 
subset of genes, leading to their repression, while concurrently establishing 3-dimensional 
contacts at a new set of genes that then become actively transcribed.  The role of enhancers 
and enhancer RNA has not been investigated in the E2-mediated repression of genes, 
however it seems plausible that the mechanisms that govern formation of 3-dimensional 
organization in response to E2 treatment at E2 inducible genes also govern the transcription 
of E2-repressed genes, prior to E2 treatment.  Whether TDG plays a role in E2-mediated 
repression is unknown.  To explore the possibility that TDG mediates E2-repression it may 
be worthwhile to compare our ChIP-Seq data with available datasets in order to establish 
TDG whether TDG is present at sites which are actively transcribed and then become 
repressed in response to E2. 
Another question that is raised by my work is whether TDG’s role at enhancers extends to 
other signaling pathways such as, TGF-β signaling, RAR-signaling.  Indeed, recent work 
by our lab in retinoic acid signaling observed that in response to retinoic acid, TDG 
activated transcription of HIC1, an RAR-target gene, through 3-dimensional re-
193 
 
 
 
organization bringing together a distal element with the promoter (Hassan et al., 2017).  
Whether eRNA production from the distal region mediates this interaction and what role, 
if any, TDG plays in these dynamics has not been investigated.  In HaCat cells for example, 
TDG activates CDKN2B in response to TGF-β through the active demethylation of the 
CDKN2B promoter (Thillainadesan et al., 2012).  Importantly, loss of TDG results in 
repression of the promoter and an inability to activate CDKN2B in response to TGF-β.  
Extending these results globally, using ChIP-Seq, found that that the demethylation of the 
CDKN2B promoter is unique, as the majority of the overlap between TDG binding and 
demethylation in response to TGF-β actually occurs intergenically, outside of annotated 
promoters. In light of recent findings that TDG mediates transcription or active 
demethylation at enhancers, it would be interesting to explore dynamics at these distal sites 
in HaCat cells that undergo TDG binding and demethylation.  Unlike enhancers in MCF7 
cells which are hypomethylated prior to TDG localization, distal sites in HaCat cells are 
methylated and, concurrent with TDG binding, undergo demethylation.  Whether these are 
enhancer sites that produce eRNA and undergo 3-dimensional reorganization remains to 
be explored.  If these sites are bonafide enhancers, they will provide us with an ideal system 
to explore the role of TDG-mediated active demethylation at enhancers: determining if its 
required for coregulator recruitment, eRNA production and 3-dimensional reorganization.   
Finally, a key finding of my work was the observation that in the MCF7 breast cancer cell 
line, TDG has both pro- and anti-tumor functionality: mediating ERα signaling while 
limiting migration and invasiveness.  In the pursuit of identifying therapeutic targets, this 
mutually-opposed pleiotropy poses an interesting challenge, namely, identifying in what 
contexts inhibition of TDG may prove to be potentially therapeutic.  While empirical tests 
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employing a wide variety of cell-lines and/or human tissues may be helpful, a global 
accounting of transcription profiles using RNA-Seq across a wide range of samples can 
expose which targets of TDG are down-regulated during TDG silencing, allowing for the 
development of ‘markers’ than can indicate under which circumstances targeting TDG can 
be effective. 
Collectively, this body of work has expanded our knowledge regarding the mechanism 
through which TDG functions and extended its role to senescence in adult tissue and 
embryonic development.  Future work extending from this research offers an exciting 
possibility to deepen our understanding of early transcriptional events that are often 
dysregulated in various human pathologies and as such may open new targets for 
therapeutic intervention. 
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